<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:02:33 -0700</creation_date>
  <update_date>2013-01-15 19:02:33 -0700</update_date>
  <accession>HMDBP02101</accession>
  <secondary_accessions>
    <accession>7583</accession>
  </secondary_accessions>
  <protein_type>Transporter</protein_type>
  <synonyms>
    <synonym>ATP-binding cassette sub-family B member 1</synonym>
    <synonym>CD243 antigen</synonym>
    <synonym>P-glycoprotein 1</synonym>
  </synonyms>
  <gene_name>ABCB1</gene_name>
  <general_function>Involved in ATP binding</general_function>
  <specific_function>Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB14322</accession>
      <name>Fluvoxamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14342</accession>
      <name>Fluconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14344</accession>
      <name>Erythromycin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01847</accession>
      <name>Caffeine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14351</accession>
      <name>Reserpine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14352</accession>
      <name>Azithromycin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14021</accession>
      <name>N-Desmethylcitalopram</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13919</accession>
      <name>N-Desmethyleletriptan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14365</accession>
      <name>Nelfinavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14369</accession>
      <name>Indinavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14372</accession>
      <name>Lovastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14379</accession>
      <name>Reboxetine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13895</accession>
      <name>3',4'-Dihydrodiol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14400</accession>
      <name>Diethylstilbestrol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14421</accession>
      <name>Amsacrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14426</accession>
      <name>Lidocaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14440</accession>
      <name>Morphine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14450</accession>
      <name>Mitomycin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14462</accession>
      <name>Gefitinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14465</accession>
      <name>Dihydroergotamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14477</accession>
      <name>Methadone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14010</accession>
      <name>5-Hydroxyomeprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14486</accession>
      <name>Terfenadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14487</accession>
      <name>Diltiazem</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14488</accession>
      <name>Protriptyline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14495</accession>
      <name>Megestrol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14500</accession>
      <name>Chlorzoxazone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14502</accession>
      <name>Mefloquine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14505</accession>
      <name>Vinorelbine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14509</accession>
      <name>Grepafloxacin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14515</accession>
      <name>Meprobamate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14517</accession>
      <name>Timolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14526</accession>
      <name>Tacrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14534</accession>
      <name>Digoxin n</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01830</accession>
      <name>Progesterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14542</accession>
      <name>Sorafenib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14545</accession>
      <name>Nisoldipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14565</accession>
      <name>Spironolactone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14572</accession>
      <name>Streptozocin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14583</accession>
      <name>Trimethoprim</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14584</accession>
      <name>Gemcitabine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14586</accession>
      <name>Betamethasone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14008</accession>
      <name>Hydroxylansoprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14600</accession>
      <name>Prazosin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14611</accession>
      <name>Quinine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14613</accession>
      <name>Dronabinol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14620</accession>
      <name>Chlorpromazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14633</accession>
      <name>Buspirone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14644</accession>
      <name>Cimetidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14645</accession>
      <name>Haloperidol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14646</accession>
      <name>Ritonavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14650</accession>
      <name>Triflupromazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14656</accession>
      <name>Cisplatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14659</accession>
      <name>Albendazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14661</accession>
      <name>Caspofungin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14671</accession>
      <name>Erlotinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13856</accession>
      <name>4-Hydroxycyclophosphamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14677</accession>
      <name>Ciprofloxacin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14679</accession>
      <name>Toremifene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14681</accession>
      <name>Vincristine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14695</accession>
      <name>Lamotrigine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14703</accession>
      <name>Methotrexate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14704</accession>
      <name>Carbamazepine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14710</accession>
      <name>Vinblastine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14722</accession>
      <name>Enalapril</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14723</accession>
      <name>Nizatidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13974</accession>
      <name>4'-Hydroxydiclofenac</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14728</accession>
      <name>Doxazosin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14740</accession>
      <name>Ivermectin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14746</accession>
      <name>Chloroquine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13862</accession>
      <name>N-desmethylimatinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14760</accession>
      <name>Nicardipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14761</accession>
      <name>Fluphenazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00234</accession>
      <name>Testosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14773</accession>
      <name>Prednisone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14775</accession>
      <name>Astemizole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14781</accession>
      <name>Mebendazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14794</accession>
      <name>Trazodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13961</accession>
      <name>O-Desmethylverapamil (D-702)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14024</accession>
      <name>2-Hydroxychlorpropamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13866</accession>
      <name>N-Desmethyltamoxifen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13846</accession>
      <name>E-3179</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14821</accession>
      <name>Midazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14828</accession>
      <name>Flurazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14832</accession>
      <name>Daunorubicin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14834</accession>
      <name>Ergotamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14839</accession>
      <name>Amprenavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14842</accession>
      <name>Naltrexone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14853</accession>
      <name>Paroxetine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14855</accession>
      <name>Norethindrone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14864</accession>
      <name>Trimipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14879</accession>
      <name>Hydrocortisone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00765</accession>
      <name>Mannitol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14889</accession>
      <name>Epinastine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14911</accession>
      <name>Etoposide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14916</accession>
      <name>Roxithromycin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00151</accession>
      <name>Estradiol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14928</accession>
      <name>Perindopril</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13842</accession>
      <name>O-Deethylated candesartan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14940</accession>
      <name>Alfentanil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14948</accession>
      <name>Biperiden</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14951</accession>
      <name>Fentanyl</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14969</accession>
      <name>Trifluoperazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14972</accession>
      <name>Mifepristone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14983</accession>
      <name>Clofazimine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14998</accession>
      <name>Prednisolone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15002</accession>
      <name>Tacrolimus</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15013</accession>
      <name>Flupenthixol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15015</accession>
      <name>Sirolimus</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15020</accession>
      <name>Clomifene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15044</accession>
      <name>Quinidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15051</accession>
      <name>Amantadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15069</accession>
      <name>Maprotiline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01895</accession>
      <name>Salicylic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01879</accession>
      <name>Aspirin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15094</accession>
      <name>Methylprednisolone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15101</accession>
      <name>Telmisartan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15102</accession>
      <name>Desloratadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15105</accession>
      <name>Dactinomycin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15108</accession>
      <name>Ezetimibe</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15110</accession>
      <name>Dipyridamole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01926</accession>
      <name>17a-Ethynylestradiol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15132</accession>
      <name>Doxorubicin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15151</accession>
      <name>Glyburide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15158</accession>
      <name>Felodipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15164</accession>
      <name>Topotecan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15166</accession>
      <name>Probenecid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15171</accession>
      <name>Selegiline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15179</accession>
      <name>Rifampin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15187</accession>
      <name>Nitrendipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15202</accession>
      <name>Promethazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15205</accession>
      <name>Atazanavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15232</accession>
      <name>Pimozide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15235</accession>
      <name>Quinacrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15242</accession>
      <name>Miconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15247</accession>
      <name>Nifedipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13946</accession>
      <name>8-Hydroxycarvedilol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15269</accession>
      <name>Sulfinpyrazone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15273</accession>
      <name>Doxepin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15280</accession>
      <name>Nefazodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15282</accession>
      <name>Desipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15293</accession>
      <name>Terazosin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15298</accession>
      <name>Itraconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15300</accession>
      <name>Arsenic trioxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15313</accession>
      <name>Propafenone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15314</accession>
      <name>Naloxone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15315</accession>
      <name>Domperidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15324</accession>
      <name>Acebutolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15327</accession>
      <name>Estramustine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15328</accession>
      <name>Captopril</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15331</accession>
      <name>Bromocriptine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15333</accession>
      <name>Levetiracetam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15334</accession>
      <name>Nadolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15335</accession>
      <name>Mitoxantrone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15336</accession>
      <name>Flumazenil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15339</accession>
      <name>Sparfloxacin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15342</accession>
      <name>Clarithromycin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15360</accession>
      <name>Paclitaxel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15362</accession>
      <name>Saquinavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15364</accession>
      <name>Dexamethasone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15369</accession>
      <name>Chlorprothixene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15372</accession>
      <name>Clomipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15374</accession>
      <name>Bepridil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15378</accession>
      <name>Docetaxel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15383</accession>
      <name>Ergonovine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15384</accession>
      <name>Dasatinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15388</accession>
      <name>Lapatinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15390</accession>
      <name>Sitagliptin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15392</accession>
      <name>Posaconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15397</accession>
      <name>Sunitinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15432</accession>
      <name>Vecuronium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15433</accession>
      <name>Cilazapril</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15448</accession>
      <name>Troleandomycin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15466</accession>
      <name>Colchicine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15468</accession>
      <name>Digitoxin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15472</accession>
      <name>Neostigmine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15523</accession>
      <name>Liotrix</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15526</accession>
      <name>Ketazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15534</accession>
      <name>Nitrazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15539</accession>
      <name>Lopinavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03217</accession>
      <name>Genistein</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00619</accession>
      <name>Cholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00131</accession>
      <name>Glycerol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00036</accession>
      <name>Taurocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00067</accession>
      <name>Cholesterol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00153</accession>
      <name>Estriol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15595</accession>
      <name>Nilotinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15597</accession>
      <name>Voacamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15632</accession>
      <name>Temsirolimus</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15641</accession>
      <name>Dabigatran etexilate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15672</accession>
      <name>Cabazitaxel</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>nucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>active transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>primary active transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>p-p-bond-hydrolysis-driven transmembrane transporter activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>atpase activity, coupled to transmembrane movement of substances</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity, acting on acid anhydrides</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>pyrophosphatase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleoside-triphosphatase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>atpase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>nucleoside binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>purine nucleoside binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adenyl nucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>adenyl ribonucleotide binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>atp binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transmembrane transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>establishment of localization</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>transport</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:7</chromosome_location>
    <locus>7q21.12</locus>
    <gene_sequence>&gt;3843 bp
ATGGATCTTGAAGGGGACCGCAATGGAGGAGCAAAGAAGAAGAACTTTTTTAAACTGAAC
AATAAAAGTGAAAAAGATAAGAAGGAAAAGAAACCAACTGTCAGTGTATTTTCAATGTTT
CGCTATTCAAATTGGCTTGACAAGTTGTATATGGTGGTGGGAACTTTGGCTGCCATCATC
CATGGGGCTGGACTTCCTCTCATGATGCTGGTGTTTGGAGAAATGACAGATATCTTTGCA
AATGCAGGAAATTTAGAAGATCTGATGTCAAACATCACTAATAGAAGTGATATCAATGAT
ACAGGGTTCTTCATGAATCTGGAGGAAGACATGACCAGGTATGCCTATTATTACAGTGGA
ATTGGTGCTGGGGTGCTGGTTGCTGCTTACATTCAGGTTTCATTTTGGTGCCTGGCAGCT
GGAAGACAAATACACAAAATTAGAAAACAGTTTTTTCATGCTATAATGCGACAGGAGATA
GGCTGGTTTGATGTGCACGATGTTGGGGAGCTTAACACCCGACTTACAGATGATGTCTCC
AAGATTAATGAAGGAATTGGTGACAAAATTGGAATGTTCTTTCAGTCAATGGCAACATTT
TTCACTGGGTTTATAGTAGGATTTACACGTGGTTGGAAGCTAACCCTTGTGATTTTGGCC
ATCAGTCCTGTTCTTGGACTGTCAGCTGCTGTCTGGGCAAAGATACTATCTTCATTTACT
GATAAAGAACTCTTAGCGTATGCAAAAGCTGGAGCAGTAGCTGAAGAGGTCTTGGCAGCA
ATTAGAACTGTGATTGCATTTGGAGGACAAAAGAAAGAACTTGAAAGGTACAACAAAAAT
TTAGAAGAAGCTAAAAGAATTGGGATAAAGAAAGCTATTACAGCCAATATTTCTATAGGT
GCTGCTTTCCTGCTGATCTATGCATCTTATGCTCTGGCCTTCTGGTATGGGACCACCTTG
GTCCTCTCAGGGGAATATTCTATTGGACAAGTACTCACTGTATTCTTTTCTGTATTAATT
GGGGCTTTTAGTGTTGGACAGGCATCTCCAAGCATTGAAGCATTTGCAAATGCAAGAGGA
GCAGCTTATGAAATCTTCAAGATAATTGATAATAAGCCAAGTATTGACAGCTATTCGAAG
AGTGGGCACAAACCAGATAATATTAAGGGAAATTTGGAATTCAGAAATGTTCACTTCAGT
TACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGTCTGAACCTGAAGGTGCAGAGTGGG
CAGACGGTGGCCCTGGTTGGAAACAGTGGCTGTGGGAAGAGCACAACAGTCCAGCTGATG
CAGAGGCTCTATGACCCCACAGAGGGGATGGTCAGTGTTGATGGACAGGATATTAGGACC
ATAAATGTAAGGTTTCTACGGGAAATCATTGGTGTGGTGAGTCAGGAACCTGTATTGTTT
GCCACCACGATAGCTGAAAACATTCGCTATGGCCGTGAAAATGTCACCATGGATGAGATT
GAGAAAGCTGTCAAGGAAGCCAATGCCTATGACTTTATCATGAAACTGCCTCATAAATTT
GACACCCTGGTTGGAGAGAGAGGGGCCCAGTTGAGTGGTGGGCAGAAGCAGAGGATCGCC
ATTGCACGTGCCCTGGTTCGCAACCCCAAGATCCTCCTGCTGGATGAGGCCACGTCAGCC
TTGGACACAGAAAGCGAAGCAGTGGTTCAGGTGGCTCTGGATAAGGCCAGAAAAGGTCGG
ACCACCATTGTGATAGCTCATCGTTTGTCTACAGTTCGTAATGCTGACGTCATCGCTGGT
TTCGATGATGGAGTCATTGTGGAGAAAGGAAATCATGATGAACTCATGAAAGAGAAAGGC
ATTTACTTCAAACTTGTCACAATGCAGACAGCAGGAAATGAAGTTGAATTAGAAAATGCA
GCTGATGAATCCAAAAGTGAAATTGATGCCTTGGAAATGTCTTCAAATGATTCAAGATCC
AGTCTAATAAGAAAAAGATCAACTCGTAGGAGTGTCCGTGGATCACAAGCCCAAGACAGA
AAGCTTAGTACCAAAGAGGCTCTGGATGAAAGTATACCTCCAGTTTCCTTTTGGAGGATT
ATGAAGCTAAATTTAACTGAATGGCCTTATTTTGTTGTTGGTGTATTTTGTGCCATTATA
AATGGAGGCCTGCAACCAGCATTTGCAATAATATTTTCAAAGATTATAGGGGTTTTTACA
AGAATTGATGATCCTGAAACAAAACGACAGAATAGTAACTTGTTTTCACTATTGTTTCTA
GCCCTTGGAATTATTTCTTTTATTACATTTTTCCTTCAGGGTTTCACATTTGGCAAAGCT
GGAGAGATCCTCACCAAGCGGCTCCGATACATGGTTTTCCGATCCATGCTCAGACAGGAT
GTGAGTTGGTTTGATGACCCTAAAAACACCACTGGAGCATTGACTACCAGGCTCGCCAAT
GATGCTGCTCAAGTTAAAGGGGCTATAGGTTCCAGGCTTGCTGTAATTACCCAGAATATA
GCAAATCTTGGGACAGGAATAATTATATCCTTCATCTATGGTTGGCAACTAACACTGTTA
CTCTTAGCAATTGTACCCATCATTGCAATAGCAGGAGTTGTTGAAATGAAAATGTTGTCT
GGACAAGCACTGAAAGATAAGAAAGAACTAGAAGGTTCTGGGAAGATCGCTACTGAAGCA
ATAGAAAACTTCCGAACCGTTGTTTCTTTGACTCAGGAGCAGAAGTTTGAACATATGTAT
GCTCAGAGTTTGCAGGTACCATACAGAAACTCTTTGAGGAAAGCACACATCTTTGGAATT
ACATTTTCCTTCACCCAGGCAATGATGTATTTTTCCTATGCTGGATGTTTCCGGTTTGGA
GCCTACTTGGTGGCACATAAACTCATGAGCTTTGAGGATGTTCTGTTAGTATTTTCAGCT
GTTGTCTTTGGTGCCATGGCCGTGGGGCAAGTCAGTTCATTTGCTCCTGACTATGCCAAA
GCCAAAATATCAGCAGCCCACATCATCATGATCATTGAAAAAACCCCTTTGATTGACAGC
TACAGCACGGAAGGCCTAATGCCGAACACATTGGAAGGAAATGTCACATTTGGTGAAGTT
GTATTCAACTATCCCACCCGACCGGACATCCCAGTGCTTCAGGGACTGAGCCTGGAGGTG
AAGAAGGGCCAGACGCTGGCTCTGGTGGGCAGCAGTGGCTGTGGGAAGAGCACAGTGGTC
CAGCTCCTGGAGCGGTTCTACGACCCCTTGGCAGGGAAAGTGCTGCTTGATGGCAAAGAA
ATAAAGCGACTGAATGTTCAGTGGCTCCGAGCACACCTGGGCATCGTGTCCCAGGAGCCC
ATCCTGTTTGACTGCAGCATTGCTGAGAACATTGCCTATGGAGACAACAGCCGGGTGGTG
TCACAGGAAGAGATTGTGAGGGCAGCAAAGGAGGCCAACATACATGCCTTCATCGAGTCA
CTGCCTAATAAATATAGCACTAAAGTAGGAGACAAAGGAACTCAGCTCTCTGGTGGCCAG
AAACAACGCATTGCCATAGCTCGTGCCCTTGTTAGACAGCCTCATATTTTGCTTTTGGAT
GAAGCCACGTCAGCTCTGGATACAGAAAGTGAAAAGGTTGTCCAAGAAGCCCTGGACAAA
GCCAGAGAAGGCCGCACCTGCATTGTGATTGCTCACCGCCTGTCCACCATCCAGAATGCA
GACTTAATAGTGGTGTTTCAGAATGGCAGAGTCAAGGAGCATGGCACGCATCAGCAGCTG
CTGGCACAGAAAGGCATCTATTTTTCAATGGTCAGTGTCCAGGCTGGAACAAAGCGCCAG
TGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>1280</residue_number>
    <molecular_weight>141477.3</molecular_weight>
    <theoretical_pi>9.44</theoretical_pi>
    <pfams>
      <pfam>
        <name>ABC_membrane</name>
        <pfam_id>PF00664</pfam_id>
      </pfam>
      <pfam>
        <name>ABC_tran</name>
        <pfam_id>PF00005</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>52-72</region>
      <region>120-140</region>
      <region>189-209</region>
      <region>216-236</region>
      <region>297-317</region>
      <region>326-346</region>
      <region>711-731</region>
      <region>757-777</region>
      <region>833-853</region>
      <region>854-874</region>
      <region>937-957</region>
      <region>974-994</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Multidrug resistance protein 1
MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII
HGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG
IGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS
KINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT
DKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG
AAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG
AAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG
QTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF
ATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA
IARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG
FDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS
SLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII
NGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA
GEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI
ANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSGKIATEA
IENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG
AYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS
YSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV
QLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV
SQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD
EATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL
LAQKGIYFSMVSVQAGTKRQ</protein_sequence>
  </protein_properties>
  <genbank_protein_id>42741659</genbank_protein_id>
  <uniprot_id>P08183</uniprot_id>
  <uniprot_name>MDR1_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>NM_000927.3</genbank_gene_id>
  <genecard_id>ABCB1</genecard_id>
  <geneatlas_id>ABCB1</geneatlas_id>
  <hgnc_id>HGNC:40</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB: Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986 Nov 7;47(3):381-9.</reference_text>
      <pubmed_id>2876781</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chen CJ, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB: Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem. 1990 Jan 5;265(1):506-14.</reference_text>
      <pubmed_id>1967175</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chen G, Duran GE, Steger KA, Lacayo NJ, Jaffrezou JP, Dumontet C, Sikic BI: Multidrug-resistant human sarcoma cells with a mutant P-glycoprotein, altered phenotype, and resistance to cyclosporins. J Biol Chem. 1997 Feb 28;272(9):5974-82.</reference_text>
      <pubmed_id>9038218</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7.  Nature. 2003 Jul 10;424(6945):157-64.</reference_text>
      <pubmed_id>12853948</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gekeler V, Weger S, Probst H: mdr1/P-glycoprotein gene segments analyzed from various human leukemic cell lines exhibiting different multidrug resistance profiles. Biochem Biophys Res Commun. 1990 Jun 15;169(2):796-802.</reference_text>
      <pubmed_id>1972623</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kioka N, Tsubota J, Kakehi Y, Komano T, Gottesman MM, Pastan I, Ueda K: P-glycoprotein gene (MDR1) cDNA from human adrenal: normal P-glycoprotein carries Gly185 with an altered pattern of multidrug resistance. Biochem Biophys Res Commun. 1989 Jul 14;162(1):224-31.</reference_text>
      <pubmed_id>2568832</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kerb R, Hoffmeyer S, Brinkmann U: ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics. 2001 Feb;2(1):51-64.</reference_text>
      <pubmed_id>11258197</pubmed_id>
    </reference>
    <reference>
      <reference_text>Begley GS, Horvath AR, Taylor JC, Higgins CF: Cytoplasmic domains of the transporter associated with antigen processing and P-glycoprotein interact with subunits of the proteasome. Mol Immunol. 2005 Jan;42(1):137-41.</reference_text>
      <pubmed_id>15488952</pubmed_id>
    </reference>
    <reference>
      <reference_text>Choi KH, Chen CJ, Kriegler M, Roninson IB: An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell. 1988 May 20;53(4):519-29.</reference_text>
      <pubmed_id>2897240</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W, Bates SE, Fojo T: Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood. 1998 Mar 1;91(5):1749-56.</reference_text>
      <pubmed_id>9473242</pubmed_id>
    </reference>
    <reference>
      <reference_text>Decleves X, Chevillard S, Charpentier C, Vielh P, Laplanche JL: A new polymorphism (N21D) in the exon 2 of the human MDR1 gene encoding the P-glycoprotein. Hum Mutat. 2000 May;15(5):486.</reference_text>
      <pubmed_id>10790226</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8.</reference_text>
      <pubmed_id>10716719</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I: Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001 Mar;69(3):169-74.</reference_text>
      <pubmed_id>11240981</pubmed_id>
    </reference>
    <reference>
      <reference_text>Honda T, Dan Y, Koyabu N, Ieiri I, Otsubo K, Higuchi S, Ohtani H, Sawada Y: Polymorphism of MDR1 gene in healthy japanese subjects: a novel SNP with an amino acid substitution (Glu108Lys). Drug Metab Pharmacokinet. 2002;17(5):479-81.</reference_text>
      <pubmed_id>15618700</pubmed_id>
    </reference>
    <reference>
      <reference_text>Itoda M, Saito Y, Komamura K, Ueno K, Kamakura S, Ozawa S, Sawada J: Twelve novel single nucleotide polymorphisms in ABCB1/MDR1 among Japanese patients with ventricular tachycardia who were administered amiodarone. Drug Metab Pharmacokinet. 2002;17(6):566-71.</reference_text>
      <pubmed_id>15618713</pubmed_id>
    </reference>
    <reference>
      <reference_text>Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S, Higuchi S, Nakamura Y: Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population. J Hum Genet. 2002;47(1):38-50.</reference_text>
      <pubmed_id>11829140</pubmed_id>
    </reference>
    <reference>
      <reference_text>Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, Zhang L, Swanson E, Datta LW, Moran T, Ravenhill G, Duerr RH, Achkar JP, Karban AS, Cho JH: MDR1 Ala893 polymorphism is associated with inflammatory bowel disease.  Am J Hum Genet. 2003 Dec;73(6):1282-92. Epub 2003 Nov 7.</reference_text>
      <pubmed_id>14610718</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers.  Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7.</reference_text>
      <pubmed_id>16959974</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants.  J Pharmacol Exp Ther. 2003 Apr;305(1):197-204.</reference_text>
        <pubmed_id>12649369</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluconazole</name>
        <accession>HMDB14342</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW: Interaction of common azole antifungals with P glycoprotein.  Antimicrob Agents Chemother. 2002 Jan;46(1):160-5.</reference_text>
        <pubmed_id>11751127</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluconazole</name>
        <accession>HMDB14342</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73.</reference_text>
        <pubmed_id>11961113</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluconazole</name>
        <accession>HMDB14342</accession>
      </metabolite>
      <reference>
        <reference_text>Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.  J Pharmacol Exp Ther. 2002 Oct;303(1):323-32.</reference_text>
        <pubmed_id>12235267</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erythromycin</name>
        <accession>HMDB14344</accession>
      </metabolite>
      <reference>
        <reference_text>Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8.</reference_text>
        <pubmed_id>8632764</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erythromycin</name>
        <accession>HMDB14344</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erythromycin</name>
        <accession>HMDB14344</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73.</reference_text>
        <pubmed_id>11961113</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erythromycin</name>
        <accession>HMDB14344</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erythromycin</name>
        <accession>HMDB14344</accession>
      </metabolite>
      <reference>
        <reference_text>Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T: Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol. 1998 Oct 9;358(3):289-94.</reference_text>
        <pubmed_id>9822896</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erythromycin</name>
        <accession>HMDB14344</accession>
      </metabolite>
      <reference>
        <reference_text>Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14.</reference_text>
        <pubmed_id>10213372</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erythromycin</name>
        <accession>HMDB14344</accession>
      </metabolite>
      <reference>
        <reference_text>Asakura E, Nakayama H, Sugie M, Zhao YL, Nadai M, Kitaichi K, Shimizu A, Miyoshi M, Takagi K, Takagi K, Hasegawa T: Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur J Pharmacol. 2004 Jan 26;484(2-3):333-9.</reference_text>
        <pubmed_id>14744620</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erythromycin</name>
        <accession>HMDB14344</accession>
      </metabolite>
      <reference>
        <reference_text>Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.  J Pharmacol Exp Ther. 2002 Oct;303(1):323-32.</reference_text>
        <pubmed_id>12235267</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erythromycin</name>
        <accession>HMDB14344</accession>
      </metabolite>
      <reference>
        <reference_text>Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. Epub 2009 Mar 25.</reference_text>
        <pubmed_id>19319690</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erythromycin</name>
        <accession>HMDB14344</accession>
      </metabolite>
      <reference>
        <reference_text>Sun H, Huang Y, Frassetto L, Benet LZ: Effects of uremic toxins on hepatic uptake and metabolism of erythromycin.  Drug Metab Dispos. 2004 Nov;32(11):1239-46. Epub 2004 Jul 30.</reference_text>
        <pubmed_id>15286055</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Caffeine</name>
        <accession>HMDB01847</accession>
      </metabolite>
      <reference>
        <reference_text>Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14.</reference_text>
        <pubmed_id>10213372</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Caffeine</name>
        <accession>HMDB01847</accession>
      </metabolite>
      <reference>
        <reference_text>Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.</reference_text>
        <pubmed_id>12954186</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reserpine</name>
        <accession>HMDB14351</accession>
      </metabolite>
      <reference>
        <reference_text>Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31.</reference_text>
        <pubmed_id>11297522</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reserpine</name>
        <accession>HMDB14351</accession>
      </metabolite>
      <reference>
        <reference_text>Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8.</reference_text>
        <pubmed_id>8632764</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reserpine</name>
        <accession>HMDB14351</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reserpine</name>
        <accession>HMDB14351</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73.</reference_text>
        <pubmed_id>11961113</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reserpine</name>
        <accession>HMDB14351</accession>
      </metabolite>
      <reference>
        <reference_text>Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72.</reference_text>
        <pubmed_id>12134945</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reserpine</name>
        <accession>HMDB14351</accession>
      </metabolite>
      <reference>
        <reference_text>Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8.</reference_text>
        <pubmed_id>12636153</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reserpine</name>
        <accession>HMDB14351</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reserpine</name>
        <accession>HMDB14351</accession>
      </metabolite>
      <reference>
        <reference_text>Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.  J Pharmacol Exp Ther. 2002 Oct;303(1):323-32.</reference_text>
        <pubmed_id>12235267</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reserpine</name>
        <accession>HMDB14351</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Azithromycin</name>
        <accession>HMDB14352</accession>
      </metabolite>
      <reference>
        <reference_text>Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW: Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603.</reference_text>
        <pubmed_id>11743742</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Azithromycin</name>
        <accession>HMDB14352</accession>
      </metabolite>
      <reference>
        <reference_text>Asakura E, Nakayama H, Sugie M, Zhao YL, Nadai M, Kitaichi K, Shimizu A, Miyoshi M, Takagi K, Takagi K, Hasegawa T: Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur J Pharmacol. 2004 Jan 26;484(2-3):333-9.</reference_text>
        <pubmed_id>14744620</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants.  J Pharmacol Exp Ther. 2003 Apr;305(1):197-204.</reference_text>
        <pubmed_id>12649369</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyleletriptan</name>
        <accession>HMDB13919</accession>
      </metabolite>
      <reference>
        <reference_text>Evans DC, O'Connor D, Lake BG, Evers R, Allen C, Hargreaves R: Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos. 2003 Jul;31(7):861-9.</reference_text>
        <pubmed_id>12814962</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nelfinavir</name>
        <accession>HMDB14365</accession>
      </metabolite>
      <reference>
        <reference_text>Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ: Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 2000 Jun 16;14(9):1287-9.</reference_text>
        <pubmed_id>10894301</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nelfinavir</name>
        <accession>HMDB14365</accession>
      </metabolite>
      <reference>
        <reference_text>Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60.</reference_text>
        <pubmed_id>10820137</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nelfinavir</name>
        <accession>HMDB14365</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nelfinavir</name>
        <accession>HMDB14365</accession>
      </metabolite>
      <reference>
        <reference_text>Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998 Jan 15;101(2):289-94.</reference_text>
        <pubmed_id>9435299</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Indinavir</name>
        <accession>HMDB14369</accession>
      </metabolite>
      <reference>
        <reference_text>Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ: Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 2000 Jun 16;14(9):1287-9.</reference_text>
        <pubmed_id>10894301</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Indinavir</name>
        <accession>HMDB14369</accession>
      </metabolite>
      <reference>
        <reference_text>Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60.</reference_text>
        <pubmed_id>10820137</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Indinavir</name>
        <accession>HMDB14369</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Indinavir</name>
        <accession>HMDB14369</accession>
      </metabolite>
      <reference>
        <reference_text>Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35.</reference_text>
        <pubmed_id>11181899</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Indinavir</name>
        <accession>HMDB14369</accession>
      </metabolite>
      <reference>
        <reference_text>Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998 Jan 15;101(2):289-94.</reference_text>
        <pubmed_id>9435299</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Indinavir</name>
        <accession>HMDB14369</accession>
      </metabolite>
      <reference>
        <reference_text>Hochman JH, Chiba M, Nishime J, Yamazaki M, Lin JH: Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther. 2000 Jan;292(1):310-8.</reference_text>
        <pubmed_id>10604964</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lovastatin</name>
        <accession>HMDB14372</accession>
      </metabolite>
      <reference>
        <reference_text>Wang E, Casciano CN, Clement RP, Johnson WW: HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res. 2001 Jun;18(6):800-6.</reference_text>
        <pubmed_id>11474784</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lovastatin</name>
        <accession>HMDB14372</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lovastatin</name>
        <accession>HMDB14372</accession>
      </metabolite>
      <reference>
        <reference_text>Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14.</reference_text>
        <pubmed_id>10213372</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reboxetine</name>
        <accession>HMDB14379</accession>
      </metabolite>
      <reference>
        <reference_text>Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants.  J Pharmacol Exp Ther. 2003 Apr;305(1):197-204.</reference_text>
        <pubmed_id>12649369</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3',4'-Dihydrodiol</name>
        <accession>HMDB13895</accession>
      </metabolite>
      <reference>
        <reference_text>Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10.</reference_text>
        <pubmed_id>17045309</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3',4'-Dihydrodiol</name>
        <accession>HMDB13895</accession>
      </metabolite>
      <reference>
        <reference_text>Luna-Tortos C, Fedrowitz M, Loscher W: Several major antiepileptic drugs are substrates for human P-glycoprotein.  Neuropharmacology. 2008 Dec;55(8):1364-75. Epub 2008 Sep 11.</reference_text>
        <pubmed_id>18824002</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylstilbestrol</name>
        <accession>HMDB14400</accession>
      </metabolite>
      <reference>
        <reference_text>Rao US, Fine RL, Scarborough GA: Antiestrogens and steroid hormones: substrates of the human P-glycoprotein.  Biochem Pharmacol. 1994 Jul 19;48(2):287-92.</reference_text>
        <pubmed_id>7914405</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amsacrine</name>
        <accession>HMDB14421</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lidocaine</name>
        <accession>HMDB14426</accession>
      </metabolite>
      <reference>
        <reference_text>Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW: Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603.</reference_text>
        <pubmed_id>11743742</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lidocaine</name>
        <accession>HMDB14426</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Morphine</name>
        <accession>HMDB14440</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Morphine</name>
        <accession>HMDB14440</accession>
      </metabolite>
      <reference>
        <reference_text>Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24.</reference_text>
        <pubmed_id>12948019</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitomycin</name>
        <accession>HMDB14450</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gefitinib</name>
        <accession>HMDB14462</accession>
      </metabolite>
      <reference>
        <reference_text>Shen J, Carcaboso AM, Hubbard KE, Tagen M, Wynn HG, Panetta JC, Waters CM, Elmeliegy MA, Stewart CF: Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Res. 2009 Jul 15;69(14):5885-92. Epub 2009 Jun 30.</reference_text>
        <pubmed_id>19567673</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dihydroergotamine</name>
        <accession>HMDB14465</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73.</reference_text>
        <pubmed_id>11961113</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dihydroergotamine</name>
        <accession>HMDB14465</accession>
      </metabolite>
      <reference>
        <reference_text>Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.  J Pharmacol Exp Ther. 2002 Oct;303(1):323-32.</reference_text>
        <pubmed_id>12235267</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methadone</name>
        <accession>HMDB14477</accession>
      </metabolite>
      <reference>
        <reference_text>Stormer E, Perloff MD, von Moltke LL, Greenblatt DJ: Methadone inhibits rhodamine123 transport in Caco-2 cells.  Drug Metab Dispos. 2001 Jul;29(7):954-6.</reference_text>
        <pubmed_id>11408360</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methadone</name>
        <accession>HMDB14477</accession>
      </metabolite>
      <reference>
        <reference_text>Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Decleves X: Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010 Aug;13(7):905-15. Epub 2009 Nov 4.</reference_text>
        <pubmed_id>19887017</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-Hydroxyomeprazole</name>
        <accession>HMDB14010</accession>
      </metabolite>
      <reference>
        <reference_text>Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF: Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.  Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):551-7.</reference_text>
        <pubmed_id>11770010</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terfenadine</name>
        <accession>HMDB14486</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terfenadine</name>
        <accession>HMDB14486</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terfenadine</name>
        <accession>HMDB14486</accession>
      </metabolite>
      <reference>
        <reference_text>Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, Reiss M: Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol. 1993 Jan 26;45(2):401-6.</reference_text>
        <pubmed_id>8094615</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terfenadine</name>
        <accession>HMDB14486</accession>
      </metabolite>
      <reference>
        <reference_text>Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14.</reference_text>
        <pubmed_id>10213372</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diltiazem</name>
        <accession>HMDB14487</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diltiazem</name>
        <accession>HMDB14487</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65.</reference_text>
        <pubmed_id>12128170</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diltiazem</name>
        <accession>HMDB14487</accession>
      </metabolite>
      <reference>
        <reference_text>Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: P-glycoprotein-mediated transcellular transport of MDR-reversing agents.  FEBS Lett. 1993 Jun 7;324(1):99-102.</reference_text>
        <pubmed_id>8099333</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Protriptyline</name>
        <accession>HMDB14488</accession>
      </metabolite>
      <reference>
        <reference_text>Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83.</reference_text>
        <pubmed_id>11082465</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Megestrol</name>
        <accession>HMDB14495</accession>
      </metabolite>
      <reference>
        <reference_text>Wang L, Yang CP, Horwitz SB, Trail PA, Casazza AM: Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate. Cancer Chemother Pharmacol. 1994;34(2):96-102.</reference_text>
        <pubmed_id>8194172</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorzoxazone</name>
        <accession>HMDB14500</accession>
      </metabolite>
      <reference>
        <reference_text>Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14.</reference_text>
        <pubmed_id>10213372</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mefloquine</name>
        <accession>HMDB14502</accession>
      </metabolite>
      <reference>
        <reference_text>Fujita R, Ishikawa M, Takayanagi M, Takayanagi Y, Sasaki K: Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine.  Methods Find Exp Clin Pharmacol. 2000 Jun;22(5):281-4.</reference_text>
        <pubmed_id>11031728</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinorelbine</name>
        <accession>HMDB14505</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Grepafloxacin</name>
        <accession>HMDB14509</accession>
      </metabolite>
      <reference>
        <reference_text>Yamaguchi H, Yano I, Hashimoto Y, Inui KI: Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2. J Pharmacol Exp Ther. 2000 Oct;295(1):360-6.</reference_text>
        <pubmed_id>10992002</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Grepafloxacin</name>
        <accession>HMDB14509</accession>
      </metabolite>
      <reference>
        <reference_text>Naruhashi K, Tamai I, Inoue N, Muraoka H, Sai Y, Suzuki N, Tsuji A: Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein. J Pharm Pharmacol. 2001 May;53(5):699-709.</reference_text>
        <pubmed_id>11370709</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Grepafloxacin</name>
        <accession>HMDB14509</accession>
      </metabolite>
      <reference>
        <reference_text>Yamaguchi H, Yano I, Saito H, Inui K: Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Pharm Res. 2004 Feb;21(2):330-8.</reference_text>
        <pubmed_id>15032316</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meprobamate</name>
        <accession>HMDB14515</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Timolol</name>
        <accession>HMDB14517</accession>
      </metabolite>
      <reference>
        <reference_text>Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A: Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol. 1996 Oct;48(10):1083-9.</reference_text>
        <pubmed_id>8953513</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrine</name>
        <accession>HMDB14526</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Tsujimoto M, Ohnishi N, Yokoyama T: Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells.  Biochem Biophys Res Commun. 2002 Mar 22;292(1):190-4.</reference_text>
        <pubmed_id>11890691</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Takagi K, Tsujimoto M, Ohnishi N, Yokoyama T: Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor mRNA. Biochem Biophys Res Commun. 2003 Jun 20;306(1):116-20.</reference_text>
        <pubmed_id>12788075</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K: Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 1999 Dec;22(12):1355-9.</reference_text>
        <pubmed_id>10746169</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35.</reference_text>
        <pubmed_id>11181899</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.</reference_text>
        <pubmed_id>11785684</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Neuhoff S, Ungell AL, Zamora I, Artursson P: pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res. 2003 Aug;20(8):1141-8.</reference_text>
        <pubmed_id>12948010</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24.</reference_text>
        <pubmed_id>12948019</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Dagenais C, Graff CL, Pollack GM: Variable modulation of opioid brain uptake by P-glycoprotein in mice.  Biochem Pharmacol. 2004 Jan 15;67(2):269-76.</reference_text>
        <pubmed_id>14698039</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Taipalensuu J, Tavelin S, Lazorova L, Svensson AC, Artursson P: Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. Eur J Pharm Sci. 2004 Jan;21(1):69-75.</reference_text>
        <pubmed_id>14706813</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R: Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther. 1992 Nov;263(2):840-5.</reference_text>
        <pubmed_id>1359120</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM: Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments] Circulation. 1999 Feb 2;99(4):552-7.</reference_text>
        <pubmed_id>9927403</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Soldner A, Christians U, Susanto M, Wacher VJ, Silverman JA, Benet LZ: Grapefruit juice activates P-glycoprotein-mediated drug transport.  Pharm Res. 1999 Apr;16(4):478-85.</reference_text>
        <pubmed_id>10227700</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26.</reference_text>
        <pubmed_id>15180340</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Yamaguchi H, Yano I, Saito H, Inui K: Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Pharm Res. 2004 Feb;21(2):330-8.</reference_text>
        <pubmed_id>15032316</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33.</reference_text>
        <pubmed_id>19806783</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H: Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84. Epub 2009 Jul 21.</reference_text>
        <pubmed_id>19631272</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91.</reference_text>
        <pubmed_id>12387747</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Leonessa F, Kim JH, Ghiorghis A, Kulawiec RJ, Hammer C, Talebian A, Clarke R: C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. J Med Chem. 2002 Jan 17;45(2):390-8.</reference_text>
        <pubmed_id>11784143</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 1992 Dec 5;267(34):24248-52.</reference_text>
        <pubmed_id>1360010</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35.</reference_text>
        <pubmed_id>11181899</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.</reference_text>
        <pubmed_id>11785684</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71.</reference_text>
        <pubmed_id>8621716</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Kim WY, Benet LZ: P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.</reference_text>
        <pubmed_id>15290871</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sorafenib</name>
        <accession>HMDB14542</accession>
      </metabolite>
      <reference>
        <reference_text>Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. Epub 2009 Sep 22.</reference_text>
        <pubmed_id>19773380</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sorafenib</name>
        <accession>HMDB14542</accession>
      </metabolite>
      <reference>
        <reference_text>Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH: Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010 Feb;9(2):319-26. Epub 2010 Jan 26.</reference_text>
        <pubmed_id>20103600</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nisoldipine</name>
        <accession>HMDB14545</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65.</reference_text>
        <pubmed_id>12128170</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Spironolactone</name>
        <accession>HMDB14565</accession>
      </metabolite>
      <reference>
        <reference_text>Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW: Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603.</reference_text>
        <pubmed_id>11743742</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Streptozocin</name>
        <accession>HMDB14572</accession>
      </metabolite>
      <reference>
        <reference_text>Brady JM, Cherrington NJ, Hartley DP, Buist SC, Li N, Klaassen CD: Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab Dispos. 2002 Jul;30(7):838-44.</reference_text>
        <pubmed_id>12065443</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethoprim</name>
        <accession>HMDB14583</accession>
      </metabolite>
      <reference>
        <reference_text>Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91.</reference_text>
        <pubmed_id>12387747</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethoprim</name>
        <accession>HMDB14583</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gemcitabine</name>
        <accession>HMDB14584</accession>
      </metabolite>
      <reference>
        <reference_text>Bergman AM, Pinedo HM, Talianidis I, Veerman G, Loves WJ, van der Wilt CL, Peters GJ: Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003 Jun 16;88(12):1963-70.</reference_text>
        <pubmed_id>12799644</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Betamethasone</name>
        <accession>HMDB14586</accession>
      </metabolite>
      <reference>
        <reference_text>Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids.  Pharm Res. 2003 Nov;20(11):1794-803.</reference_text>
        <pubmed_id>14661924</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxylansoprazole</name>
        <accession>HMDB14008</accession>
      </metabolite>
      <reference>
        <reference_text>Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF: Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.  Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):551-7.</reference_text>
        <pubmed_id>11770010</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxylansoprazole</name>
        <accession>HMDB14008</accession>
      </metabolite>
      <reference>
        <reference_text>Kodaira C, Sugimoto M, Nishino M, Yamade M, Shirai N, Uchida S, Ikuma M, Yamada S, Watanabe H, Hishida A, Furuta T: Effect of MDR1 C3435T polymorphism on lansoprazole in healthy Japanese subjects.  Eur J Clin Pharmacol. 2009 Jun;65(6):593-600. Epub 2009 Feb 24.</reference_text>
        <pubmed_id>19238367</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33.</reference_text>
        <pubmed_id>19806783</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. Epub 2010 Apr 27.</reference_text>
        <pubmed_id>20423956</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazosin</name>
        <accession>HMDB14600</accession>
      </metabolite>
      <reference>
        <reference_text>Dey S, Ramachandra M, Pastan I, Gottesman MM, Ambudkar SV: Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein.  Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10594-9.</reference_text>
        <pubmed_id>9380680</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinine</name>
        <accession>HMDB14611</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinine</name>
        <accession>HMDB14611</accession>
      </metabolite>
      <reference>
        <reference_text>van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD: Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci. 2000 Sep;11(3):207-14.</reference_text>
        <pubmed_id>11042226</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinine</name>
        <accession>HMDB14611</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinine</name>
        <accession>HMDB14611</accession>
      </metabolite>
      <reference>
        <reference_text>Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71.</reference_text>
        <pubmed_id>8621716</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dronabinol</name>
        <accession>HMDB14613</accession>
      </metabolite>
      <reference>
        <reference_text>Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Decleves X: Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010 Aug;13(7):905-15. Epub 2009 Nov 4.</reference_text>
        <pubmed_id>19887017</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorpromazine</name>
        <accession>HMDB14620</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorpromazine</name>
        <accession>HMDB14620</accession>
      </metabolite>
      <reference>
        <reference_text>Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.  Life Sci. 2002 May 31;71(2):163-9.</reference_text>
        <pubmed_id>12031686</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Buspirone</name>
        <accession>HMDB14633</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cimetidine</name>
        <accession>HMDB14644</accession>
      </metabolite>
      <reference>
        <reference_text>Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91.</reference_text>
        <pubmed_id>12387747</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cimetidine</name>
        <accession>HMDB14644</accession>
      </metabolite>
      <reference>
        <reference_text>Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE: Influence of passive permeability on apparent P-glycoprotein kinetics.  Pharm Res. 2000 Dec;17(12):1456-60.</reference_text>
        <pubmed_id>11303953</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cimetidine</name>
        <accession>HMDB14644</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cimetidine</name>
        <accession>HMDB14644</accession>
      </metabolite>
      <reference>
        <reference_text>van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD: Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci. 2000 Sep;11(3):207-14.</reference_text>
        <pubmed_id>11042226</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cimetidine</name>
        <accession>HMDB14644</accession>
      </metabolite>
      <reference>
        <reference_text>Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60.</reference_text>
        <pubmed_id>9262363</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cimetidine</name>
        <accession>HMDB14644</accession>
      </metabolite>
      <reference>
        <reference_text>Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.</reference_text>
        <pubmed_id>11785684</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Haloperidol</name>
        <accession>HMDB14645</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Haloperidol</name>
        <accession>HMDB14645</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Haloperidol</name>
        <accession>HMDB14645</accession>
      </metabolite>
      <reference>
        <reference_text>Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.  Life Sci. 2002 May 31;71(2):163-9.</reference_text>
        <pubmed_id>12031686</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ritonavir</name>
        <accession>HMDB14646</accession>
      </metabolite>
      <reference>
        <reference_text>Perloff MD, Von Moltke LL, Marchand JE, Greenblatt DJ: Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci. 2001 Nov;90(11):1829-37.</reference_text>
        <pubmed_id>11745741</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ritonavir</name>
        <accession>HMDB14646</accession>
      </metabolite>
      <reference>
        <reference_text>Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60.</reference_text>
        <pubmed_id>10820137</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ritonavir</name>
        <accession>HMDB14646</accession>
      </metabolite>
      <reference>
        <reference_text>Kumar S, Kwei GY, Poon GK, Iliff SA, Wang Y, Chen Q, Franklin RB, Didolkar V, Wang RW, Yamazaki M, Chiu SH, Lin JH, Pearson PG, Baillie TA: Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther. 2003 Mar;304(3):1161-71.</reference_text>
        <pubmed_id>12604693</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ritonavir</name>
        <accession>HMDB14646</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ritonavir</name>
        <accession>HMDB14646</accession>
      </metabolite>
      <reference>
        <reference_text>Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35.</reference_text>
        <pubmed_id>11181899</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ritonavir</name>
        <accession>HMDB14646</accession>
      </metabolite>
      <reference>
        <reference_text>Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH: P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol. 2001 Apr;59(4):806-13.</reference_text>
        <pubmed_id>11259625</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ritonavir</name>
        <accession>HMDB14646</accession>
      </metabolite>
      <reference>
        <reference_text>Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24.</reference_text>
        <pubmed_id>12948019</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ritonavir</name>
        <accession>HMDB14646</accession>
      </metabolite>
      <reference>
        <reference_text>Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.</reference_text>
        <pubmed_id>11785684</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triflupromazine</name>
        <accession>HMDB14650</accession>
      </metabolite>
      <reference>
        <reference_text>Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83.</reference_text>
        <pubmed_id>11082465</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cisplatin</name>
        <accession>HMDB14656</accession>
      </metabolite>
      <reference>
        <reference_text>Li D, Jang SH, Kim J, Wientjes MG, Au JL: Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res. 2003 Jan;20(1):45-50.</reference_text>
        <pubmed_id>12608535</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Albendazole</name>
        <accession>HMDB14659</accession>
      </metabolite>
      <reference>
        <reference_text>Merino G, Alvarez AI, Prieto JG, Kim RB: The anthelminthic agent albendazole does not interact with p-glycoprotein.  Drug Metab Dispos. 2002 Apr;30(4):365-9.</reference_text>
        <pubmed_id>11901088</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Caspofungin</name>
        <accession>HMDB14661</accession>
      </metabolite>
      <reference>
        <reference_text>Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent caspofungin.  Drug Metab Dispos. 2005 May;33(5):676-82. Epub 2005 Feb 16.</reference_text>
        <pubmed_id>15716364</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erlotinib</name>
        <accession>HMDB14671</accession>
      </metabolite>
      <reference>
        <reference_text>Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH: Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008 Aug;7(8):2280-7.</reference_text>
        <pubmed_id>18723475</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-Hydroxycyclophosphamide</name>
        <accession>HMDB13856</accession>
      </metabolite>
      <reference>
        <reference_text>Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW: Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603.</reference_text>
        <pubmed_id>11743742</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ciprofloxacin</name>
        <accession>HMDB14677</accession>
      </metabolite>
      <reference>
        <reference_text>Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW: Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603.</reference_text>
        <pubmed_id>11743742</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ciprofloxacin</name>
        <accession>HMDB14677</accession>
      </metabolite>
      <reference>
        <reference_text>Yamaguchi H, Yano I, Saito H, Inui K: Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats. Pharm Res. 2004 Feb;21(2):330-8.</reference_text>
        <pubmed_id>15032316</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Toremifene</name>
        <accession>HMDB14679</accession>
      </metabolite>
      <reference>
        <reference_text>Rao US, Fine RL, Scarborough GA: Antiestrogens and steroid hormones: substrates of the human P-glycoprotein.  Biochem Pharmacol. 1994 Jul 19;48(2):287-92.</reference_text>
        <pubmed_id>7914405</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Arora A, Shukla Y: Modulation of vinca-alkaloid induced P-glycoprotein expression by indole-3-carbinol. Cancer Lett. 2003 Jan 28;189(2):167-73.</reference_text>
        <pubmed_id>12490309</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72.</reference_text>
        <pubmed_id>12134945</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Doppenschmitt S, Langguth P, Regardh CG, Andersson TB, Hilgendorf C, Spahn-Langguth H: Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. J Pharmacol Exp Ther. 1999 Jan;288(1):348-57.</reference_text>
        <pubmed_id>9862789</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Li D, Jang SH, Kim J, Wientjes MG, Au JL: Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res. 2003 Jan;20(1):45-50.</reference_text>
        <pubmed_id>12608535</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35.</reference_text>
        <pubmed_id>10617675</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY: BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res. 2004 Jul 1;64(13):4621-8.</reference_text>
        <pubmed_id>15231674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ: MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8. Epub 2009 Jan 4.</reference_text>
        <pubmed_id>19123050</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. Epub 2009 Apr 11.</reference_text>
        <pubmed_id>19427995</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. Epub 2009 May 12.</reference_text>
        <pubmed_id>19493273</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lamotrigine</name>
        <accession>HMDB14695</accession>
      </metabolite>
      <reference>
        <reference_text>Luna-Tortos C, Fedrowitz M, Loscher W: Several major antiepileptic drugs are substrates for human P-glycoprotein.  Neuropharmacology. 2008 Dec;55(8):1364-75. Epub 2008 Sep 11.</reference_text>
        <pubmed_id>18824002</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methotrexate</name>
        <accession>HMDB14703</accession>
      </metabolite>
      <reference>
        <reference_text>Norris MD, De Graaf D, Haber M, Kavallaris M, Madafiglio J, Gilbert J, Kwan E, Stewart BW, Mechetner EB, Gudkov AV, Roninson IB: Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate.  Int J Cancer. 1996 Mar 1;65(5):613-9.</reference_text>
        <pubmed_id>8598312</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbamazepine</name>
        <accession>HMDB14704</accession>
      </metabolite>
      <reference>
        <reference_text>Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31.</reference_text>
        <pubmed_id>11297522</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbamazepine</name>
        <accession>HMDB14704</accession>
      </metabolite>
      <reference>
        <reference_text>Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK: Carbamazepine is not a substrate for P-glycoprotein.  Br J Clin Pharmacol. 2001 Apr;51(4):345-9.</reference_text>
        <pubmed_id>11318771</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbamazepine</name>
        <accession>HMDB14704</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbamazepine</name>
        <accession>HMDB14704</accession>
      </metabolite>
      <reference>
        <reference_text>Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10.</reference_text>
        <pubmed_id>17045309</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbamazepine</name>
        <accession>HMDB14704</accession>
      </metabolite>
      <reference>
        <reference_text>Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.</reference_text>
        <pubmed_id>12954186</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Arora A, Shukla Y: Modulation of vinca-alkaloid induced P-glycoprotein expression by indole-3-carbinol. Cancer Lett. 2003 Jan 28;189(2):167-73.</reference_text>
        <pubmed_id>12490309</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6.</reference_text>
        <pubmed_id>11405287</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72.</reference_text>
        <pubmed_id>12134945</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8.</reference_text>
        <pubmed_id>12636153</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R: Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther. 1992 Nov;263(2):840-5.</reference_text>
        <pubmed_id>1359120</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Tiberghien F, Loor F: Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs. 1996 Jul;7(5):568-78.</reference_text>
        <pubmed_id>8862725</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Pouliot JF, L'Heureux F, Liu Z, Prichard RK, Georges E: Reversal of P-glycoprotein-associated multidrug resistance by ivermectin.  Biochem Pharmacol. 1997 Jan 10;53(1):17-25.</reference_text>
        <pubmed_id>8960059</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Smit JW, Weert B, Schinkel AH, Meijer DK: Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs. J Pharmacol Exp Ther. 1998 Jul;286(1):321-7.</reference_text>
        <pubmed_id>9655875</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Shepard RL, Winter MA, Hsaio SC, Pearce HL, Beck WT, Dantzig AH: Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein. Biochem Pharmacol. 1998 Sep 15;56(6):719-27.</reference_text>
        <pubmed_id>9751076</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R: P-glycoprotein inhibition by glibenclamide and related compounds.  Pflugers Arch. 1999 Apr;437(5):652-60.</reference_text>
        <pubmed_id>10087141</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K: Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 1999 Dec;22(12):1355-9.</reference_text>
        <pubmed_id>10746169</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22.</reference_text>
        <pubmed_id>15616150</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35.</reference_text>
        <pubmed_id>11181899</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.</reference_text>
        <pubmed_id>11785684</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Kumar S, Kwei GY, Poon GK, Iliff SA, Wang Y, Chen Q, Franklin RB, Didolkar V, Wang RW, Yamazaki M, Chiu SH, Lin JH, Pearson PG, Baillie TA: Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther. 2003 Mar;304(3):1161-71.</reference_text>
        <pubmed_id>12604693</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Atkinson DE, Greenwood SL, Sibley CP, Glazier JD, Fairbairn LJ: Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. Am J Physiol Cell Physiol. 2003 Sep;285(3):C584-91. Epub 2003 Apr 30.</reference_text>
        <pubmed_id>12724138</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24.</reference_text>
        <pubmed_id>12948019</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Dagenais C, Graff CL, Pollack GM: Variable modulation of opioid brain uptake by P-glycoprotein in mice.  Biochem Pharmacol. 2004 Jan 15;67(2):269-76.</reference_text>
        <pubmed_id>14698039</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Taipalensuu J, Tavelin S, Lazorova L, Svensson AC, Artursson P: Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. Eur J Pharm Sci. 2004 Jan;21(1):69-75.</reference_text>
        <pubmed_id>14706813</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Hunter J, Hirst BH, Simmons NL: Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm Res. 1993 May;10(5):743-9.</reference_text>
        <pubmed_id>8100632</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71.</reference_text>
        <pubmed_id>8621716</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Dantzig AH, Shepard RL, Law KL, Tabas L, Pratt S, Gillespie JS, Binkley SN, Kuhfeld MT, Starling JJ, Wrighton SA: Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther. 1999 Aug;290(2):854-62.</reference_text>
        <pubmed_id>10411602</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35.</reference_text>
        <pubmed_id>10617675</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Fedoruk MN, Gimenez-Bonafe P, Guns ES, Mayer LD, Nelson CC: P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells. Prostate. 2004 Apr 1;59(1):77-90.</reference_text>
        <pubmed_id>14991868</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33.</reference_text>
        <pubmed_id>19806783</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H: Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84. Epub 2009 Jul 21.</reference_text>
        <pubmed_id>19631272</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Kugawa F, Suzuki T, Miyata M, Tomono K, Tamanoi F: Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells. Pharmazie. 2009 May;64(5):296-300.</reference_text>
        <pubmed_id>19530439</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ: MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8. Epub 2009 Jan 4.</reference_text>
        <pubmed_id>19123050</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol. 2002 May;61(5):974-81.</reference_text>
        <pubmed_id>11961114</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M, Nishiguchi K, Okumura K: Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull. 2002 Jun;25(6):771-8.</reference_text>
        <pubmed_id>12081145</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Henning U, Loffler S, Krieger K, Klimke A: Uptake of clozapine into HL-60 promyelocytic leukaemia cells.  Pharmacopsychiatry. 2002 May;35(3):90-5.</reference_text>
        <pubmed_id>12107852</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9.</reference_text>
        <pubmed_id>12134946</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.  J Pharmacol Exp Ther. 2002 Oct;303(1):323-32.</reference_text>
        <pubmed_id>12235267</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Enalapril</name>
        <accession>HMDB14722</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1.  Life Sci. 2002 Feb 15;70(13):1491-500.</reference_text>
        <pubmed_id>11895100</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nizatidine</name>
        <accession>HMDB14723</accession>
      </metabolite>
      <reference>
        <reference_text>Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. Epub 2009 Mar 25.</reference_text>
        <pubmed_id>19319690</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4'-Hydroxydiclofenac</name>
        <accession>HMDB13974</accession>
      </metabolite>
      <reference>
        <reference_text>Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW: Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603.</reference_text>
        <pubmed_id>11743742</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxazosin</name>
        <accession>HMDB14728</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1.  Life Sci. 2002 Feb 15;70(13):1491-500.</reference_text>
        <pubmed_id>11895100</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxazosin</name>
        <accession>HMDB14728</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33.</reference_text>
        <pubmed_id>19806783</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ivermectin</name>
        <accession>HMDB14740</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ivermectin</name>
        <accession>HMDB14740</accession>
      </metabolite>
      <reference>
        <reference_text>Pouliot JF, L'Heureux F, Liu Z, Prichard RK, Georges E: Reversal of P-glycoprotein-associated multidrug resistance by ivermectin.  Biochem Pharmacol. 1997 Jan 10;53(1):17-25.</reference_text>
        <pubmed_id>8960059</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ivermectin</name>
        <accession>HMDB14740</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ivermectin</name>
        <accession>HMDB14740</accession>
      </metabolite>
      <reference>
        <reference_text>Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P: Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995 Oct;96(4):1698-705.</reference_text>
        <pubmed_id>7560060</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ivermectin</name>
        <accession>HMDB14740</accession>
      </metabolite>
      <reference>
        <reference_text>Jani M, Makai I, Kis E, Szabo P, Nagy T, Krajcsi P, Lespine A: Ivermectin interacts with human ABCG2.  J Pharm Sci. 2011 Jan;100(1):94-7. doi: 10.1002/jps.22262. Epub 2010 Jun 22.</reference_text>
        <pubmed_id>20574995</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chloroquine</name>
        <accession>HMDB14746</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, Harris RJ, Jorgensen HG, Holyoake TL, Pirmohamed M, Clark RE, Mountford JC: Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia. 2009 Nov;23(11):1999-2006. Epub 2009 Aug 27.</reference_text>
        <pubmed_id>19710702</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. Epub 2010 Apr 27.</reference_text>
        <pubmed_id>20423956</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Hamada A, Miyano H, Watanabe H, Saito H: Interaction of imatinib mesilate with human P-glycoprotein.  J Pharmacol Exp Ther. 2003 Nov;307(2):824-8. Epub 2003 Sep 15.</reference_text>
        <pubmed_id>12975485</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Thomas J, Wang L, Clark RE, Pirmohamed M: Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004 Dec 1;104(12):3739-45. Epub 2004 Aug 17.</reference_text>
        <pubmed_id>15315971</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. Epub 2009 Sep 28.</reference_text>
        <pubmed_id>19785662</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE: Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood. 2008 Oct 15;112(8):3348-54. Epub 2008 Jul 31.</reference_text>
        <pubmed_id>18669873</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH: The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 2005 Apr 1;65(7):2577-82.</reference_text>
        <pubmed_id>15805252</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Oka M, Fukuda M, Soda H: [Anticancer drugs and ABC transporters].  Gan To Kagaku Ryoho. 2005 May;32(5):585-92.</reference_text>
        <pubmed_id>15918555</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K: Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52. Epub 2005 Jul 9.</reference_text>
        <pubmed_id>15970668</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Galimberti S, Cervetti G, Guerrini F, Testi R, Pacini S, Fazzi R, Simi P, Petrini M: Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment. Cancer Genet Cytogenet. 2005 Oct 1;162(1):57-62.</reference_text>
        <pubmed_id>16157201</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Gardner ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA, Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, Figg WD, Verweij J, Sparreboom A, Nooter K: Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther. 2006 Aug;80(2):192-201.</reference_text>
        <pubmed_id>16890580</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nicardipine</name>
        <accession>HMDB14760</accession>
      </metabolite>
      <reference>
        <reference_text>Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4. Pharm Res. 2000 Oct;17(10):1189-97.</reference_text>
        <pubmed_id>11145223</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nicardipine</name>
        <accession>HMDB14760</accession>
      </metabolite>
      <reference>
        <reference_text>Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE: Influence of passive permeability on apparent P-glycoprotein kinetics.  Pharm Res. 2000 Dec;17(12):1456-60.</reference_text>
        <pubmed_id>11303953</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nicardipine</name>
        <accession>HMDB14760</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nicardipine</name>
        <accession>HMDB14760</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65.</reference_text>
        <pubmed_id>12128170</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nicardipine</name>
        <accession>HMDB14760</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nicardipine</name>
        <accession>HMDB14760</accession>
      </metabolite>
      <reference>
        <reference_text>Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83.</reference_text>
        <pubmed_id>11082465</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nicardipine</name>
        <accession>HMDB14760</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluphenazine</name>
        <accession>HMDB14761</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Testosterone</name>
        <accession>HMDB00234</accession>
      </metabolite>
      <reference>
        <reference_text>Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001 Feb;12(4):505-13.</reference_text>
        <pubmed_id>11231118</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Testosterone</name>
        <accession>HMDB00234</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prednisone</name>
        <accession>HMDB14773</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prednisone</name>
        <accession>HMDB14773</accession>
      </metabolite>
      <reference>
        <reference_text>Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids.  Pharm Res. 2003 Nov;20(11):1794-803.</reference_text>
        <pubmed_id>14661924</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Astemizole</name>
        <accession>HMDB14775</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Astemizole</name>
        <accession>HMDB14775</accession>
      </metabolite>
      <reference>
        <reference_text>Ishikawa M, Fujita R, Takayanagi M, Takayanagi Y, Sasaki K: Reversal of acquired resistance to doxorubicin in K562 human leukemia cells by astemizole. Biol Pharm Bull. 2000 Jan;23(1):112-5.</reference_text>
        <pubmed_id>10706423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mebendazole</name>
        <accession>HMDB14781</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trazodone</name>
        <accession>HMDB14794</accession>
      </metabolite>
      <reference>
        <reference_text>Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ: P-glycoprotein interactions of nefazodone and trazodone in cell culture.  J Clin Pharmacol. 2001 Jul;41(7):708-14.</reference_text>
        <pubmed_id>11452702</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ: Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 2000 Jun 16;14(9):1287-9.</reference_text>
        <pubmed_id>10894301</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91.</reference_text>
        <pubmed_id>12387747</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60.</reference_text>
        <pubmed_id>10820137</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, Sugiyama Y: Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems. Drug Metab Dispos. 2000 Oct;28(10):1238-43.</reference_text>
        <pubmed_id>10997946</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Fujita R, Ishikawa M, Takayanagi M, Takayanagi Y, Sasaki K: Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine.  Methods Find Exp Clin Pharmacol. 2000 Jun;22(5):281-4.</reference_text>
        <pubmed_id>11031728</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6.</reference_text>
        <pubmed_id>11405287</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Leonessa F, Kim JH, Ghiorghis A, Kulawiec RJ, Hammer C, Talebian A, Clarke R: C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. J Med Chem. 2002 Jan 17;45(2):390-8.</reference_text>
        <pubmed_id>11784143</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72.</reference_text>
        <pubmed_id>12134945</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Zhang S, Morris ME: Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther. 2003 Mar;304(3):1258-67.</reference_text>
        <pubmed_id>12604704</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8.</reference_text>
        <pubmed_id>12636153</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>van der Sandt IC, Blom-Roosemalen MC, de Boer AG, Breimer DD: Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur J Pharm Sci. 2000 Sep;11(3):207-14.</reference_text>
        <pubmed_id>11042226</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83.</reference_text>
        <pubmed_id>11082465</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos. 2001 Aug;29(8):1080-3.</reference_text>
        <pubmed_id>11454724</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants.  J Pharmacol Exp Ther. 2003 Apr;305(1):197-204.</reference_text>
        <pubmed_id>12649369</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D: Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol. 1994 Oct 7;48(7):1528-30.</reference_text>
        <pubmed_id>7945455</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, Reiss M: Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol. 1993 Jan 26;45(2):401-6.</reference_text>
        <pubmed_id>8094615</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Pouliot JF, L'Heureux F, Liu Z, Prichard RK, Georges E: Reversal of P-glycoprotein-associated multidrug resistance by ivermectin.  Biochem Pharmacol. 1997 Jan 10;53(1):17-25.</reference_text>
        <pubmed_id>8960059</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Kuhnel JM, Perrot JY, Faussat AM, Marie JP, Schwaller MA: Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe. Leukemia. 1997 Jul;11(7):1147-55.</reference_text>
        <pubmed_id>9205004</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Kim AE, Dintaman JM, Waddell DS, Silverman JA: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein.  J Pharmacol Exp Ther. 1998 Sep;286(3):1439-45.</reference_text>
        <pubmed_id>9732409</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Bebawy M, Morris MB, Roufogalis BD: A continuous fluorescence assay for the study of P-glycoprotein-mediated drug efflux using inside-out membrane vesicles. Anal Biochem. 1999 Mar 15;268(2):270-7.</reference_text>
        <pubmed_id>10075817</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R: P-glycoprotein inhibition by glibenclamide and related compounds.  Pflugers Arch. 1999 Apr;437(5):652-60.</reference_text>
        <pubmed_id>10087141</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K: Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol. 1999 Dec 1;58(11):1801-6.</reference_text>
        <pubmed_id>10571255</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Eagling VA, Profit L, Back DJ: Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol. 1999 Oct;48(4):543-52.</reference_text>
        <pubmed_id>10583025</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Choi CH, Kim JH, Kim SH: Reversal of P-glycoprotein-mediated MDR by 5,7,3',4',5'-pentamethoxyflavone and SAR. Biochem Biophys Res Commun. 2004 Jul 30;320(3):672-9.</reference_text>
        <pubmed_id>15240100</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004 Dec;143(7):856-64. Epub 2004 Oct 25.</reference_text>
        <pubmed_id>15504753</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Hu K, Morris ME: Effects of benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates on P-glycoprotein- and MRP1-mediated transport. J Pharm Sci. 2004 Jul;93(7):1901-11.</reference_text>
        <pubmed_id>15176077</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Lee BH, Lee CO, Kwon MJ, Yi KY, Yoo SE, Choi SU: Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity. Anticancer Drugs. 2003 Feb;14(2):175-81.</reference_text>
        <pubmed_id>12569305</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Petri N, Tannergren C, Rungstad D, Lennernas H: Transport characteristics of fexofenadine in the Caco-2 cell model.  Pharm Res. 2004 Aug;21(8):1398-404.</reference_text>
        <pubmed_id>15359574</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10.</reference_text>
        <pubmed_id>17045309</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Santoni-Rugiu E, Silverman JA: Functional characterization of the rat mdr1b encoded P-glycoprotein: not all inducing agents are substrates. Carcinogenesis. 1997 Nov;18(11):2255-63.</reference_text>
        <pubmed_id>9395229</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Sieczkowski E, Lehner C, Ambros PF, Hohenegger M: Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Int J Cancer. 2010 May 1;126(9):2025-35.</reference_text>
        <pubmed_id>19739078</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Chiu LY, Ko JL, Lee YJ, Yang TY, Tee YT, Sheu GT: L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18. Epub 2009 Nov 26.</reference_text>
        <pubmed_id>19944135</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Karlsson JE, Heddle C, Rozkov A, Rotticci-Mulder J, Tuvesson O, Hilgendorf C, Andersson TB: High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells. Drug Metab Dispos. 2010 Apr;38(4):705-14. Epub 2010 Jan 13.</reference_text>
        <pubmed_id>20071452</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H: Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84. Epub 2009 Jul 21.</reference_text>
        <pubmed_id>19631272</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Kugawa F, Suzuki T, Miyata M, Tomono K, Tamanoi F: Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells. Pharmazie. 2009 May;64(5):296-300.</reference_text>
        <pubmed_id>19530439</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. Epub 2009 Jun       18.</reference_text>
        <pubmed_id>19541926</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. Epub 2009 May 12.</reference_text>
        <pubmed_id>19493273</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. Epub 2009 Mar 25.</reference_text>
        <pubmed_id>19319690</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm MF: Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther. 2000 May;293(2):376-82.</reference_text>
        <pubmed_id>10773005</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.</reference_text>
        <pubmed_id>11785684</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24.</reference_text>
        <pubmed_id>12948019</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.</reference_text>
        <pubmed_id>12954186</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Dagenais C, Graff CL, Pollack GM: Variable modulation of opioid brain uptake by P-glycoprotein in mice.  Biochem Pharmacol. 2004 Jan 15;67(2):269-76.</reference_text>
        <pubmed_id>14698039</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71.</reference_text>
        <pubmed_id>8621716</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26.</reference_text>
        <pubmed_id>15180340</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Tfelt-Hansen P, Tfelt-Hansen J: Verapamil for cluster headache. Clinical pharmacology and possible mode of action. Headache. 2009 Jan;49(1):117-25.</reference_text>
        <pubmed_id>19125880</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>2-Hydroxychlorpropamide</name>
        <accession>HMDB14024</accession>
      </metabolite>
      <reference>
        <reference_text>Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83.</reference_text>
        <pubmed_id>11082465</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Riley J, Styles J, Verschoyle RD, Stanley LA, White IN, Gant TW: Association of tamoxifen biliary excretion rate with prior tamoxifen exposure and increased mdr1b expression. Biochem Pharmacol. 2000 Jul 15;60(2):233-9.</reference_text>
        <pubmed_id>10825468</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14.</reference_text>
        <pubmed_id>10213372</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Bekaii-Saab TS, Perloff MD, Weemhoff JL, Greenblatt DJ, von Moltke LL: Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A. Biopharm Drug Dispos. 2004 Oct;25(7):283-9.</reference_text>
        <pubmed_id>15386482</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35.</reference_text>
        <pubmed_id>10617675</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>E-3179</name>
        <accession>HMDB13846</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1.  Life Sci. 2002 Feb 15;70(13):1491-500.</reference_text>
        <pubmed_id>11895100</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>E-3179</name>
        <accession>HMDB13846</accession>
      </metabolite>
      <reference>
        <reference_text>Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71.</reference_text>
        <pubmed_id>8621716</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>E-3179</name>
        <accession>HMDB13846</accession>
      </metabolite>
      <reference>
        <reference_text>Soldner A, Benet LZ, Mutschler E, Christians U: Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol. 2000 Mar;129(6):1235-43.</reference_text>
        <pubmed_id>10725273</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8.</reference_text>
        <pubmed_id>8632764</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001 Feb;12(4):505-13.</reference_text>
        <pubmed_id>11231118</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T: Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol. 1998 Oct 9;358(3):289-94.</reference_text>
        <pubmed_id>9822896</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14.</reference_text>
        <pubmed_id>10213372</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurazepam</name>
        <accession>HMDB14828</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou G, Kuo MT: Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin. J Biol Chem. 1998 Jun 19;273(25):15387-94.</reference_text>
        <pubmed_id>9624121</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6.</reference_text>
        <pubmed_id>11405287</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72.</reference_text>
        <pubmed_id>12134945</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K: Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 1999 Dec;22(12):1355-9.</reference_text>
        <pubmed_id>10746169</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Tang F, Ouyang H, Yang JZ, Borchardt RT: Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-MDR1 cell monolayers. J Pharm Sci. 2004 May;93(5):1185-94.</reference_text>
        <pubmed_id>15067695</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.</reference_text>
        <pubmed_id>11785684</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35.</reference_text>
        <pubmed_id>10617675</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33.</reference_text>
        <pubmed_id>19806783</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Borska S, Sopel M, Chmielewska M, Zabel M, Dziegiel P: Quercetin as a potential modulator of P-glycoprotein expression and function in cells of human pancreatic carcinoma line resistant to daunorubicin. Molecules. 2010 Feb 9;15(2):857-70.</reference_text>
        <pubmed_id>20335952</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Perez-Victoria JM, Chiquero MJ, Conseil G, Dayan G, Di Pietro A, Barron D, Castanys S, Gamarro F: Correlation between the affinity of flavonoids binding to the cytosolic site of Leishmania tropica multidrug transporter and their efficiency to revert parasite resistance to daunomycin. Biochemistry. 1999 Feb 9;38(6):1736-43.</reference_text>
        <pubmed_id>10026252</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Pallis M, Turzanski J, Harrison G, Wheatley K, Langabeer S, Burnett AK, Russell NH: Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia. Br J Haematol. 1999 Feb;104(2):307-12.</reference_text>
        <pubmed_id>10050713</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Chiodini B, Bassan R, Barbui T: Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells. Leuk Lymphoma. 1999 May;33(5-6):485-97.</reference_text>
        <pubmed_id>10342576</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Romsicki Y, Sharom FJ: The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry. 1999 May 25;38(21):6887-96.</reference_text>
        <pubmed_id>10346910</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Hiessbock R, Wolf C, Richter E, Hitzler M, Chiba P, Kratzel M, Ecker G: Synthesis and in vitro multidrug resistance modulating activity of a series of dihydrobenzopyrans and tetrahydroquinolines. J Med Chem. 1999 Jun 3;42(11):1921-6.</reference_text>
        <pubmed_id>10354400</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergotamine</name>
        <accession>HMDB14834</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73.</reference_text>
        <pubmed_id>11961113</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergotamine</name>
        <accession>HMDB14834</accession>
      </metabolite>
      <reference>
        <reference_text>Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.  J Pharmacol Exp Ther. 2002 Oct;303(1):323-32.</reference_text>
        <pubmed_id>12235267</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amprenavir</name>
        <accession>HMDB14839</accession>
      </metabolite>
      <reference>
        <reference_text>Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ: Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 2000 Jun 16;14(9):1287-9.</reference_text>
        <pubmed_id>10894301</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amprenavir</name>
        <accession>HMDB14839</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naltrexone</name>
        <accession>HMDB14842</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paroxetine</name>
        <accession>HMDB14853</accession>
      </metabolite>
      <reference>
        <reference_text>Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants.  J Pharmacol Exp Ther. 2003 Apr;305(1):197-204.</reference_text>
        <pubmed_id>12649369</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norethindrone</name>
        <accession>HMDB14855</accession>
      </metabolite>
      <reference>
        <reference_text>Kim WY, Benet LZ: P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.</reference_text>
        <pubmed_id>15290871</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimipramine</name>
        <accession>HMDB14864</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocortisone</name>
        <accession>HMDB14879</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocortisone</name>
        <accession>HMDB14879</accession>
      </metabolite>
      <reference>
        <reference_text>Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14.</reference_text>
        <pubmed_id>10213372</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocortisone</name>
        <accession>HMDB14879</accession>
      </metabolite>
      <reference>
        <reference_text>Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids.  Pharm Res. 2003 Nov;20(11):1794-803.</reference_text>
        <pubmed_id>14661924</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocortisone</name>
        <accession>HMDB14879</accession>
      </metabolite>
      <reference>
        <reference_text>Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 1992 Dec 5;267(34):24248-52.</reference_text>
        <pubmed_id>1360010</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocortisone</name>
        <accession>HMDB14879</accession>
      </metabolite>
      <reference>
        <reference_text>Orlowski S, Mir LM, Belehradek J Jr, Garrigos M: Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators. Biochem J. 1996 Jul 15;317 ( Pt 2):515-22.</reference_text>
        <pubmed_id>8713080</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mannitol</name>
        <accession>HMDB00765</accession>
      </metabolite>
      <reference>
        <reference_text>Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.</reference_text>
        <pubmed_id>12954186</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Epinastine</name>
        <accession>HMDB14889</accession>
      </metabolite>
      <reference>
        <reference_text>Ishiguro N, Nozawa T, Tsujihata A, Saito A, Kishimoto W, Yokoyama K, Yotsumoto T, Sakai K, Igarashi T, Tamai I: Influx and efflux transport of H1-antagonist epinastine across the blood-brain barrier. Drug Metab Dispos. 2004 May;32(5):519-24.</reference_text>
        <pubmed_id>15100174</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etoposide</name>
        <accession>HMDB14911</accession>
      </metabolite>
      <reference>
        <reference_text>Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6.</reference_text>
        <pubmed_id>11405287</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etoposide</name>
        <accession>HMDB14911</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etoposide</name>
        <accession>HMDB14911</accession>
      </metabolite>
      <reference>
        <reference_text>Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72.</reference_text>
        <pubmed_id>12134945</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etoposide</name>
        <accession>HMDB14911</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etoposide</name>
        <accession>HMDB14911</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etoposide</name>
        <accession>HMDB14911</accession>
      </metabolite>
      <reference>
        <reference_text>Guo A, Marinaro W, Hu P, Sinko PJ: Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.</reference_text>
        <pubmed_id>11901101</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etoposide</name>
        <accession>HMDB14911</accession>
      </metabolite>
      <reference>
        <reference_text>Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24.</reference_text>
        <pubmed_id>12948019</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Roxithromycin</name>
        <accession>HMDB14916</accession>
      </metabolite>
      <reference>
        <reference_text>Beltinger J, Haschke M, Kaufmann P, Michot M, Terracciano L, Krahenbuhl S: Hepatic veno-occlusive disease associated with immunosuppressive cyclophosphamide dosing and roxithromycin. Ann Pharmacother. 2006 Apr;40(4):767-70. Epub 2006 Mar 7.</reference_text>
        <pubmed_id>16595573</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Roxithromycin</name>
        <accession>HMDB14916</accession>
      </metabolite>
      <reference>
        <reference_text>Kaufmann P, Haschke M, Torok M, Beltinger J, Bogman K, Wenk M, Terracciano L, Krahenbuhl S: Mechanisms of venoocclusive disease resulting from the combination of cyclophosphamide and roxithromycin. Ther Drug Monit. 2006 Dec;28(6):766-74.</reference_text>
        <pubmed_id>17164692</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estradiol</name>
        <accession>HMDB00151</accession>
      </metabolite>
      <reference>
        <reference_text>Rao US, Fine RL, Scarborough GA: Antiestrogens and steroid hormones: substrates of the human P-glycoprotein.  Biochem Pharmacol. 1994 Jul 19;48(2):287-92.</reference_text>
        <pubmed_id>7914405</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estradiol</name>
        <accession>HMDB00151</accession>
      </metabolite>
      <reference>
        <reference_text>Kim WY, Benet LZ: P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.</reference_text>
        <pubmed_id>15290871</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Perindopril</name>
        <accession>HMDB14928</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1.  Life Sci. 2002 Feb 15;70(13):1491-500.</reference_text>
        <pubmed_id>11895100</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Deethylated candesartan</name>
        <accession>HMDB13842</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1.  Life Sci. 2002 Feb 15;70(13):1491-500.</reference_text>
        <pubmed_id>11895100</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfentanil</name>
        <accession>HMDB14940</accession>
      </metabolite>
      <reference>
        <reference_text>Wandel C, Kim R, Wood M, Wood A: Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology. 2002 Apr;96(4):913-20.</reference_text>
        <pubmed_id>11964599</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Biperiden</name>
        <accession>HMDB14948</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fentanyl</name>
        <accession>HMDB14951</accession>
      </metabolite>
      <reference>
        <reference_text>Wandel C, Kim R, Wood M, Wood A: Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology. 2002 Apr;96(4):913-20.</reference_text>
        <pubmed_id>11964599</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluoperazine</name>
        <accession>HMDB14969</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mifepristone</name>
        <accession>HMDB14972</accession>
      </metabolite>
      <reference>
        <reference_text>Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31.</reference_text>
        <pubmed_id>11297522</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mifepristone</name>
        <accession>HMDB14972</accession>
      </metabolite>
      <reference>
        <reference_text>Lecureur V, Fardel O, Guillouzo A: The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS Lett. 1994 Nov 28;355(2):187-91.</reference_text>
        <pubmed_id>7982498</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clofazimine</name>
        <accession>HMDB14983</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prednisolone</name>
        <accession>HMDB14998</accession>
      </metabolite>
      <reference>
        <reference_text>Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24.</reference_text>
        <pubmed_id>12948019</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prednisolone</name>
        <accession>HMDB14998</accession>
      </metabolite>
      <reference>
        <reference_text>Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids.  Pharm Res. 2003 Nov;20(11):1794-803.</reference_text>
        <pubmed_id>14661924</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrolimus</name>
        <accession>HMDB15002</accession>
      </metabolite>
      <reference>
        <reference_text>Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8.</reference_text>
        <pubmed_id>8632764</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrolimus</name>
        <accession>HMDB15002</accession>
      </metabolite>
      <reference>
        <reference_text>Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T: Human P-glycoprotein transports cyclosporin A and FK506.  J Biol Chem. 1993 Mar 25;268(9):6077-80.</reference_text>
        <pubmed_id>7681059</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrolimus</name>
        <accession>HMDB15002</accession>
      </metabolite>
      <reference>
        <reference_text>Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ: P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res. 1999 Aug 15;59(16):3944-8.</reference_text>
        <pubmed_id>10463589</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrolimus</name>
        <accession>HMDB15002</accession>
      </metabolite>
      <reference>
        <reference_text>Hashida T, Masuda S, Uemoto S, Saito H, Tanaka K, Inui K: Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation. Clin Pharmacol Ther. 2001 May;69(5):308-16.</reference_text>
        <pubmed_id>11371998</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrolimus</name>
        <accession>HMDB15002</accession>
      </metabolite>
      <reference>
        <reference_text>Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26.</reference_text>
        <pubmed_id>15180340</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrolimus</name>
        <accession>HMDB15002</accession>
      </metabolite>
      <reference>
        <reference_text>Quezada CA, Garrido WX, Gonzalez-Oyarzun MA, Rauch MC, Salas MR, San Martin RE, Claude AA, Yanez AJ, Slebe JC, Carcamo JG: Effect of tacrolimus on activity and expression of P-glycoprotein and ATP-binding cassette transporter A5 (ABCA5) proteins in hematoencephalic barrier cells. Biol Pharm Bull. 2008 Oct;31(10):1911-6.</reference_text>
        <pubmed_id>18827354</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flupenthixol</name>
        <accession>HMDB15013</accession>
      </metabolite>
      <reference>
        <reference_text>Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, Reiss M: Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol. 1993 Jan 26;45(2):401-6.</reference_text>
        <pubmed_id>8094615</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flupenthixol</name>
        <accession>HMDB15013</accession>
      </metabolite>
      <reference>
        <reference_text>Dey S, Hafkemeyer P, Pastan I, Gottesman MM: A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol. Biochemistry. 1999 May 18;38(20):6630-9.</reference_text>
        <pubmed_id>10350482</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flupenthixol</name>
        <accession>HMDB15013</accession>
      </metabolite>
      <reference>
        <reference_text>Hafkemeyer P, Licht T, Pastan I, Gottesman MM: Chemoprotection of hematopoietic cells by a mutant P-glycoprotein resistant to a potent chemosensitizer of multidrug-resistant cancers. Hum Gene Ther. 2000 Mar 1;11(4):555-65.</reference_text>
        <pubmed_id>10724034</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flupenthixol</name>
        <accession>HMDB15013</accession>
      </metabolite>
      <reference>
        <reference_text>Yang JM, Vassil A, Hait WN: Involvement of phosphatidylinositol-3-kinase in membrane ruffling induced by P-glycoprotein substrates in multidrug-resistant carcinoma cells. Biochem Pharmacol. 2002 Mar 1;63(5):959-66.</reference_text>
        <pubmed_id>11911848</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flupenthixol</name>
        <accession>HMDB15013</accession>
      </metabolite>
      <reference>
        <reference_text>Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN: Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res. 1990 Mar 15;50(6):1748-56.</reference_text>
        <pubmed_id>1968358</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flupenthixol</name>
        <accession>HMDB15013</accession>
      </metabolite>
      <reference>
        <reference_text>Ford JM, Yang JM, Hait WN: Effect of buthionine sulfoximine on toxicity of verapamil and doxorubicin to multidrug resistant cells and to mice. Cancer Res. 1991 Jan 1;51(1):67-72.</reference_text>
        <pubmed_id>1988108</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sirolimus</name>
        <accession>HMDB15015</accession>
      </metabolite>
      <reference>
        <reference_text>Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8.</reference_text>
        <pubmed_id>8632764</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sirolimus</name>
        <accession>HMDB15015</accession>
      </metabolite>
      <reference>
        <reference_text>Wacher VJ, Silverman JA, Wong S, Tran-Tau P, Chan AO, Chai A, Yu XQ, O'Mahony D, Ramtoola Z: Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinate. J Pharmacol Exp Ther. 2002 Oct;303(1):308-13.</reference_text>
        <pubmed_id>12235265</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sirolimus</name>
        <accession>HMDB15015</accession>
      </metabolite>
      <reference>
        <reference_text>Arceci RJ, Stieglitz K, Bierer BE: Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood. 1992 Sep 15;80(6):1528-36.</reference_text>
        <pubmed_id>1381629</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sirolimus</name>
        <accession>HMDB15015</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomifene</name>
        <accession>HMDB15020</accession>
      </metabolite>
      <reference>
        <reference_text>Rao US, Fine RL, Scarborough GA: Antiestrogens and steroid hormones: substrates of the human P-glycoprotein.  Biochem Pharmacol. 1994 Jul 19;48(2):287-92.</reference_text>
        <pubmed_id>7914405</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60.</reference_text>
        <pubmed_id>10820137</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6.</reference_text>
        <pubmed_id>11405287</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72.</reference_text>
        <pubmed_id>12134945</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Horie K, Tang F, Borchardt RT: Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res. 2003 Feb;20(2):161-8.</reference_text>
        <pubmed_id>12636153</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants.  J Pharmacol Exp Ther. 2003 Apr;305(1):197-204.</reference_text>
        <pubmed_id>12649369</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R: Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther. 1992 Nov;263(2):840-5.</reference_text>
        <pubmed_id>1359120</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Ito T, Yano I, Tanaka K, Inui KI: Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997 Aug;282(2):955-60.</reference_text>
        <pubmed_id>9262363</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998 Jan 15;101(2):289-94.</reference_text>
        <pubmed_id>9435299</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H: Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84. Epub 2009 Jul 21.</reference_text>
        <pubmed_id>19631272</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Dahan A, Amidon GL: Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7. Epub 2009 Jun       18.</reference_text>
        <pubmed_id>19541926</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. Epub 2009 Mar 25.</reference_text>
        <pubmed_id>19319690</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Smith BJ, Doran AC, McLean S, Tingley FD 3rd, O'Neill BT, Kajiji SM: P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1252-9.</reference_text>
        <pubmed_id>11504828</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.</reference_text>
        <pubmed_id>11785684</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Neuhoff S, Ungell AL, Zamora I, Artursson P: pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res. 2003 Aug;20(8):1141-8.</reference_text>
        <pubmed_id>12948010</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24.</reference_text>
        <pubmed_id>12948019</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.</reference_text>
        <pubmed_id>12954186</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM: Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments] Circulation. 1999 Feb 2;99(4):552-7.</reference_text>
        <pubmed_id>9927403</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amantadine</name>
        <accession>HMDB15051</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Maprotiline</name>
        <accession>HMDB15069</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Maprotiline</name>
        <accession>HMDB15069</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Salicylic acid</name>
        <accession>HMDB01895</accession>
      </metabolite>
      <reference>
        <reference_text>Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.</reference_text>
        <pubmed_id>12954186</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aspirin</name>
        <accession>HMDB01879</accession>
      </metabolite>
      <reference>
        <reference_text>Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.</reference_text>
        <pubmed_id>12954186</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylprednisolone</name>
        <accession>HMDB15094</accession>
      </metabolite>
      <reference>
        <reference_text>Oka A, Oda M, Saitoh H, Nakayama A, Takada M, Aungst BJ: Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol Pharm Bull. 2002 Mar;25(3):393-6.</reference_text>
        <pubmed_id>11913542</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylprednisolone</name>
        <accession>HMDB15094</accession>
      </metabolite>
      <reference>
        <reference_text>Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24.</reference_text>
        <pubmed_id>12948019</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylprednisolone</name>
        <accession>HMDB15094</accession>
      </metabolite>
      <reference>
        <reference_text>Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids.  Pharm Res. 2003 Nov;20(11):1794-803.</reference_text>
        <pubmed_id>14661924</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Telmisartan</name>
        <accession>HMDB15101</accession>
      </metabolite>
      <reference>
        <reference_text>Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61.</reference_text>
        <pubmed_id>20222053</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desloratadine</name>
        <accession>HMDB15102</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos. 2001 Aug;29(8):1080-3.</reference_text>
        <pubmed_id>11454724</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dactinomycin</name>
        <accession>HMDB15105</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dactinomycin</name>
        <accession>HMDB15105</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dactinomycin</name>
        <accession>HMDB15105</accession>
      </metabolite>
      <reference>
        <reference_text>Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, Pastan I: Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8472-6.</reference_text>
        <pubmed_id>1356264</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ezetimibe</name>
        <accession>HMDB15108</accession>
      </metabolite>
      <reference>
        <reference_text>Oswald S, Nassif A, Modess C, Keiser M, Ulrich A, Runge D, Hanke U, Lutjohann D, Engel A, Weitschies W, Siegmund W: Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8. Epub 2011 Mar 2.</reference_text>
        <pubmed_id>21368751</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dipyridamole</name>
        <accession>HMDB15110</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dipyridamole</name>
        <accession>HMDB15110</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>17a-Ethynylestradiol</name>
        <accession>HMDB01926</accession>
      </metabolite>
      <reference>
        <reference_text>Kim WY, Benet LZ: P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.</reference_text>
        <pubmed_id>15290871</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Fardel O, Lecureur V, Daval S, Corlu A, Guillouzo A: Up-regulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem. 1997 May 15;246(1):186-92.</reference_text>
        <pubmed_id>9210482</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6.</reference_text>
        <pubmed_id>11405287</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K: Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 1999 Dec;22(12):1355-9.</reference_text>
        <pubmed_id>10746169</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Jutabha P, Wempe MF, Anzai N, Otomo J, Kadota T, Endou H: Xenopus laevis oocytes expressing human P-glycoprotein: probing trans- and cis-inhibitory effects on [3H]vinblastine and [3H]digoxin efflux. Pharmacol Res. 2010 Jan;61(1):76-84. Epub 2009 Jul 21.</reference_text>
        <pubmed_id>19631272</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Li D, Jang SH, Kim J, Wientjes MG, Au JL: Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res. 2003 Jan;20(1):45-50.</reference_text>
        <pubmed_id>12608535</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24.</reference_text>
        <pubmed_id>12948019</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Kim S, Kim SS, Bang YJ, Kim SJ, Lee BJ: In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides. 2003 Jul;24(7):945-53.</reference_text>
        <pubmed_id>14499271</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, Pastan I: Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8472-6.</reference_text>
        <pubmed_id>1356264</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Kusunoki N, Takara K, Tanigawara Y, Yamauchi A, Ueda K, Komada F, Ku Y, Kuroda Y, Saitoh Y, Okumura K: Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein. Jpn J Cancer Res. 1998 Nov;89(11):1220-8.</reference_text>
        <pubmed_id>9914792</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Li YC, Fung KP, Kwok TT, Lee CY, Suen YK, Kong SK: Mitochondria-targeting drug oligomycin blocked P-glycoprotein activity and triggered apoptosis in doxorubicin-resistant HepG2 cells. Chemotherapy. 2004 Jun;50(2):55-62.</reference_text>
        <pubmed_id>15211078</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Sieczkowski E, Lehner C, Ambros PF, Hohenegger M: Double impact on p-glycoprotein by statins enhances doxorubicin cytotoxicity in human neuroblastoma cells. Int J Cancer. 2010 May 1;126(9):2025-35.</reference_text>
        <pubmed_id>19739078</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV: Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9. Epub 2010 Feb 23.</reference_text>
        <pubmed_id>20179710</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Tao LY, Liang YJ, Wang F, Chen LM, Yan YY, Dai CL, Fu LW: Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother Pharmacol. 2009 Oct;64(5):961-9. Epub 2009 Mar 3.</reference_text>
        <pubmed_id>19255759</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ: MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8. Epub 2009 Jan 4.</reference_text>
        <pubmed_id>19123050</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glyburide</name>
        <accession>HMDB15151</accession>
      </metabolite>
      <reference>
        <reference_text>Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R: P-glycoprotein inhibition by glibenclamide and related compounds.  Pflugers Arch. 1999 Apr;437(5):652-60.</reference_text>
        <pubmed_id>10087141</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Felodipine</name>
        <accession>HMDB15158</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Topotecan</name>
        <accession>HMDB15164</accession>
      </metabolite>
      <reference>
        <reference_text>Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26.</reference_text>
        <pubmed_id>15180340</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Topotecan</name>
        <accession>HMDB15164</accession>
      </metabolite>
      <reference>
        <reference_text>Carcaboso AM, Elmeliegy MA, Shen J, Juel SJ, Zhang ZM, Calabrese C, Tracey L, Waters CM, Stewart CF: Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.  Cancer Res. 2010 Jun 1;70(11):4499-508. Epub 2010 May 11.</reference_text>
        <pubmed_id>20460504</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Topotecan</name>
        <accession>HMDB15164</accession>
      </metabolite>
      <reference>
        <reference_text>Shen J, Carcaboso AM, Hubbard KE, Tagen M, Wynn HG, Panetta JC, Waters CM, Elmeliegy MA, Stewart CF: Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Res. 2009 Jul 15;69(14):5885-92. Epub 2009 Jun 30.</reference_text>
        <pubmed_id>19567673</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Probenecid</name>
        <accession>HMDB15166</accession>
      </metabolite>
      <reference>
        <reference_text>Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6.</reference_text>
        <pubmed_id>11405287</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Probenecid</name>
        <accession>HMDB15166</accession>
      </metabolite>
      <reference>
        <reference_text>Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004 Dec;143(7):856-64. Epub 2004 Oct 25.</reference_text>
        <pubmed_id>15504753</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Probenecid</name>
        <accession>HMDB15166</accession>
      </metabolite>
      <reference>
        <reference_text>Minderman H, Brooks TA, O'Loughlin KL, Ojima I, Bernacki RJ, Baer MR: Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023. Cancer Chemother Pharmacol. 2004 May;53(5):363-9. Epub 2004 Jan 27.</reference_text>
        <pubmed_id>15060738</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifampin</name>
        <accession>HMDB15179</accession>
      </metabolite>
      <reference>
        <reference_text>Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31.</reference_text>
        <pubmed_id>11297522</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifampin</name>
        <accession>HMDB15179</accession>
      </metabolite>
      <reference>
        <reference_text>Schuetz EG, Beck WT, Schuetz JD: Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996 Feb;49(2):311-8.</reference_text>
        <pubmed_id>8632764</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifampin</name>
        <accession>HMDB15179</accession>
      </metabolite>
      <reference>
        <reference_text>Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK: The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.  J Clin Invest. 1999 Jul;104(2):147-53.</reference_text>
        <pubmed_id>10411543</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifampin</name>
        <accession>HMDB15179</accession>
      </metabolite>
      <reference>
        <reference_text>Fardel O, Lecureur V, Loyer P, Guillouzo A: Rifampicin enhances anti-cancer drug accumulation and activity in multidrug-resistant cells. Biochem Pharmacol. 1995 May 11;49(9):1255-60.</reference_text>
        <pubmed_id>7763306</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifampin</name>
        <accession>HMDB15179</accession>
      </metabolite>
      <reference>
        <reference_text>Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26.</reference_text>
        <pubmed_id>15180340</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifampin</name>
        <accession>HMDB15179</accession>
      </metabolite>
      <reference>
        <reference_text>Kuypers DR, Verleden G, Naesens M, Vanrenterghem Y: Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase. Clin Pharmacol Ther. 2005 Jul;78(1):81-8.</reference_text>
        <pubmed_id>16003296</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifampin</name>
        <accession>HMDB15179</accession>
      </metabolite>
      <reference>
        <reference_text>Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, Cheboyina S: Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. 2006 Jan;34(1):69-74. Epub 2005 Oct 12.</reference_text>
        <pubmed_id>16221754</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifampin</name>
        <accession>HMDB15179</accession>
      </metabolite>
      <reference>
        <reference_text>Chen J, Raymond K: Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob. 2006 Feb 15;5:3.</reference_text>
        <pubmed_id>16480505</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifampin</name>
        <accession>HMDB15179</accession>
      </metabolite>
      <reference>
        <reference_text>Lamba J, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, Cheng C, Lamba V, Watkins PB, Schuetz E: MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther. 2006 Apr;79(4):325-38. Epub 2006 Feb 20.</reference_text>
        <pubmed_id>16580901</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifampin</name>
        <accession>HMDB15179</accession>
      </metabolite>
      <reference>
        <reference_text>Huang R, Murry DJ, Kolwankar D, Hall SD, Foster DR: Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem Pharmacol. 2006 Jun 14;71(12):1695-704. Epub 2006 Apr 18.</reference_text>
        <pubmed_id>16620787</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitrendipine</name>
        <accession>HMDB15187</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitrendipine</name>
        <accession>HMDB15187</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65.</reference_text>
        <pubmed_id>12128170</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promethazine</name>
        <accession>HMDB15202</accession>
      </metabolite>
      <reference>
        <reference_text>Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83.</reference_text>
        <pubmed_id>11082465</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atazanavir</name>
        <accession>HMDB15205</accession>
      </metabolite>
      <reference>
        <reference_text>Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, von Moltke LL: Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro.  Drug Metab Dispos. 2005 Jun;33(6):764-70. Epub 2005 Mar 11.</reference_text>
        <pubmed_id>15764714</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atazanavir</name>
        <accession>HMDB15205</accession>
      </metabolite>
      <reference>
        <reference_text>Lucia MB, Golotta C, Rutella S, Rastrelli E, Savarino A, Cauda R: Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):635-7.</reference_text>
        <pubmed_id>16044020</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atazanavir</name>
        <accession>HMDB15205</accession>
      </metabolite>
      <reference>
        <reference_text>Chinn LW, Gow JM, Tse MM, Becker SL, Kroetz DL: Interindividual variability in the effect of atazanavir and saquinavir on the expression of lymphocyte P-glycoprotein. J Antimicrob Chemother. 2007 Jul;60(1):61-7. Epub 2007 May 17.</reference_text>
        <pubmed_id>17510066</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atazanavir</name>
        <accession>HMDB15205</accession>
      </metabolite>
      <reference>
        <reference_text>Wood R: Atazanavir: its role in HIV treatment.  Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96.</reference_text>
        <pubmed_id>19053892</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atazanavir</name>
        <accession>HMDB15205</accession>
      </metabolite>
      <reference>
        <reference_text>Janneh O, Anwar T, Jungbauer C, Kopp S, Khoo SH, Back DJ, Chiba P: P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir. Antivir Ther. 2009;14(7):965-74.</reference_text>
        <pubmed_id>19918100</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atazanavir</name>
        <accession>HMDB15205</accession>
      </metabolite>
      <reference>
        <reference_text>Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J: Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein.  Biochem Pharmacol. 2007 May 15;73(10):1573-81. Epub 2007 Jan 24.</reference_text>
        <pubmed_id>17328866</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pimozide</name>
        <accession>HMDB15232</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pimozide</name>
        <accession>HMDB15232</accession>
      </metabolite>
      <reference>
        <reference_text>Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83.</reference_text>
        <pubmed_id>11082465</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinacrine</name>
        <accession>HMDB15235</accession>
      </metabolite>
      <reference>
        <reference_text>Tiberghien F, Loor F: Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs. 1996 Jul;7(5):568-78.</reference_text>
        <pubmed_id>8862725</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Miconazole</name>
        <accession>HMDB15242</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73.</reference_text>
        <pubmed_id>11961113</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Miconazole</name>
        <accession>HMDB15242</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Miconazole</name>
        <accession>HMDB15242</accession>
      </metabolite>
      <reference>
        <reference_text>Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.  J Pharmacol Exp Ther. 2002 Oct;303(1):323-32.</reference_text>
        <pubmed_id>12235267</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nifedipine</name>
        <accession>HMDB15247</accession>
      </metabolite>
      <reference>
        <reference_text>Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31.</reference_text>
        <pubmed_id>11297522</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nifedipine</name>
        <accession>HMDB15247</accession>
      </metabolite>
      <reference>
        <reference_text>Katoh M, Nakajima M, Yamazaki H, Yokoi T: Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci. 2001 Feb;12(4):505-13.</reference_text>
        <pubmed_id>11231118</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nifedipine</name>
        <accession>HMDB15247</accession>
      </metabolite>
      <reference>
        <reference_text>Wang E, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW: Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4. Chem Res Toxicol. 2001 Dec;14(12):1596-603.</reference_text>
        <pubmed_id>11743742</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nifedipine</name>
        <accession>HMDB15247</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65.</reference_text>
        <pubmed_id>12128170</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nifedipine</name>
        <accession>HMDB15247</accession>
      </metabolite>
      <reference>
        <reference_text>Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14.</reference_text>
        <pubmed_id>10213372</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nifedipine</name>
        <accession>HMDB15247</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nifedipine</name>
        <accession>HMDB15247</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>8-Hydroxycarvedilol</name>
        <accession>HMDB13946</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>8-Hydroxycarvedilol</name>
        <accession>HMDB13946</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1.  Life Sci. 2002 Feb 15;70(13):1491-500.</reference_text>
        <pubmed_id>11895100</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>8-Hydroxycarvedilol</name>
        <accession>HMDB13946</accession>
      </metabolite>
      <reference>
        <reference_text>Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K: Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity. Biochem Pharmacol. 1999 Dec 1;58(11):1801-6.</reference_text>
        <pubmed_id>10571255</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>8-Hydroxycarvedilol</name>
        <accession>HMDB13946</accession>
      </metabolite>
      <reference>
        <reference_text>Neuhoff S, Langguth P, Dressler C, Andersson TB, Regardh CG, Spahn-Langguth H: Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites. Int J Clin Pharmacol Ther. 2000 Apr;38(4):168-79.</reference_text>
        <pubmed_id>10783826</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>8-Hydroxycarvedilol</name>
        <accession>HMDB13946</accession>
      </metabolite>
      <reference>
        <reference_text>Hokama N, Hobara N, Sakai M, Kameya H, Ohshiro S, Sakanashi M: Influence of nicardipine and nifedipine on plasma carvedilol disposition after oral administration in rats. J Pharm Pharmacol. 2002 Jun;54(6):821-5.</reference_text>
        <pubmed_id>12078998</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>8-Hydroxycarvedilol</name>
        <accession>HMDB13946</accession>
      </metabolite>
      <reference>
        <reference_text>Kakumoto M, Sakaeda T, Takara K, Nakamura T, Kita T, Yagami T, Kobayashi H, Okamura N, Okumura K: Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil. Cancer Sci. 2003 Jan;94(1):81-6.</reference_text>
        <pubmed_id>12708479</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>8-Hydroxycarvedilol</name>
        <accession>HMDB13946</accession>
      </metabolite>
      <reference>
        <reference_text>Brodde OE, Kroemer HK: Drug-drug interactions of beta-adrenoceptor blockers.  Arzneimittelforschung. 2003;53(12):814-22.</reference_text>
        <pubmed_id>14732961</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfinpyrazone</name>
        <accession>HMDB15269</accession>
      </metabolite>
      <reference>
        <reference_text>Honda Y, Ushigome F, Koyabu N, Morimoto S, Shoyama Y, Uchiumi T, Kuwano M, Ohtani H, Sawada Y: Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol. 2004 Dec;143(7):856-64. Epub 2004 Oct 25.</reference_text>
        <pubmed_id>15504753</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxepin</name>
        <accession>HMDB15273</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nefazodone</name>
        <accession>HMDB15280</accession>
      </metabolite>
      <reference>
        <reference_text>Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ: P-glycoprotein interactions of nefazodone and trazodone in cell culture.  J Clin Pharmacol. 2001 Jul;41(7):708-14.</reference_text>
        <pubmed_id>11452702</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terazosin</name>
        <accession>HMDB15293</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33.</reference_text>
        <pubmed_id>19806783</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Itraconazole</name>
        <accession>HMDB15298</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Itraconazole</name>
        <accession>HMDB15298</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW: Interaction of common azole antifungals with P glycoprotein.  Antimicrob Agents Chemother. 2002 Jan;46(1):160-5.</reference_text>
        <pubmed_id>11751127</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Itraconazole</name>
        <accession>HMDB15298</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Itraconazole</name>
        <accession>HMDB15298</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K: Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 1999 Dec;22(12):1355-9.</reference_text>
        <pubmed_id>10746169</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Itraconazole</name>
        <accession>HMDB15298</accession>
      </metabolite>
      <reference>
        <reference_text>Masuda S, Inui K: [Molecular mechanisms on drug transporters in the drug absorption and disposition]. Nihon Rinsho. 2002 Jan;60(1):65-73.</reference_text>
        <pubmed_id>11808341</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Itraconazole</name>
        <accession>HMDB15298</accession>
      </metabolite>
      <reference>
        <reference_text>Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ: Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther. 2003 Mar;73(3):192-8.</reference_text>
        <pubmed_id>12621384</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Itraconazole</name>
        <accession>HMDB15298</accession>
      </metabolite>
      <reference>
        <reference_text>Sakaeda T, Iwaki K, Kakumoto M, Nishikawa M, Niwa T, Jin JS, Nakamura T, Nishiguchi K, Okamura N, Okumura K: Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol. 2005 Jun;57(6):759-64.</reference_text>
        <pubmed_id>15969931</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Itraconazole</name>
        <accession>HMDB15298</accession>
      </metabolite>
      <reference>
        <reference_text>Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R: Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK). Eur J Clin Pharmacol. 2005 Aug;61(7):531-6. Epub 2005 Jul 23.</reference_text>
        <pubmed_id>16041596</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Itraconazole</name>
        <accession>HMDB15298</accession>
      </metabolite>
      <reference>
        <reference_text>Shon JH, Yoon YR, Hong WS, Nguyen PM, Lee SS, Choi YG, Cha IJ, Shin JG: Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther. 2005 Aug;78(2):191-201.</reference_text>
        <pubmed_id>16084853</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Arsenic trioxide</name>
        <accession>HMDB15300</accession>
      </metabolite>
      <reference>
        <reference_text>Hu XM, Hirano T, Oka K: Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. Cancer Chemother Pharmacol. 2003 Feb;51(2):119-26. Epub 2002 Nov 20.</reference_text>
        <pubmed_id>12647012</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Arsenic trioxide</name>
        <accession>HMDB15300</accession>
      </metabolite>
      <reference>
        <reference_text>Wei HL, Yao XJ, Li YN, Wang P, Zhao HS, Bai DC, Peng X, Ma LF: [Arsenic trioxide inhibits P-glycoprotein expression in multidrug-resistant human leukemia K562/ADM cell line that overexpresses mdr-1 gene and enhances their chemotherapeutic sensitivity]. Zhonghua Xue Ye Xue Za Zhi. 2003 Jan;24(1):28-31.</reference_text>
        <pubmed_id>12679007</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Arsenic trioxide</name>
        <accession>HMDB15300</accession>
      </metabolite>
      <reference>
        <reference_text>Wei H, Su H, Bai D, Zhao H, Ge J, Wang B, Yao X, Ma L: Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene. Chin Med J (Engl). 2003 Nov;116(11):1644-8.</reference_text>
        <pubmed_id>14642128</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Arsenic trioxide</name>
        <accession>HMDB15300</accession>
      </metabolite>
      <reference>
        <reference_text>Kimura A, Ishida Y, Wada T, Yokoyama H, Mukaida N, Kondo T: MRP-1 expression levels determine strain-specific susceptibility to sodium arsenic-induced renal injury between C57BL/6 and BALB/c mice. Toxicol Appl Pharmacol. 2005 Feb 15;203(1):53-61.</reference_text>
        <pubmed_id>15694464</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Arsenic trioxide</name>
        <accession>HMDB15300</accession>
      </metabolite>
      <reference>
        <reference_text>Cronin CJ, Mendel JE, Mukhtar S, Kim YM, Stirbl RC, Bruck J, Sternberg PW: An automated system for measuring parameters of nematode sinusoidal movement.  BMC Genet. 2005 Feb 7;6:5.</reference_text>
        <pubmed_id>15698479</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propafenone</name>
        <accession>HMDB15313</accession>
      </metabolite>
      <reference>
        <reference_text>Schmid D, Ecker G, Kopp S, Hitzler M, Chiba P: Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. Biochem Pharmacol. 1999 Nov 1;58(9):1447-56.</reference_text>
        <pubmed_id>10513988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propafenone</name>
        <accession>HMDB15313</accession>
      </metabolite>
      <reference>
        <reference_text>Bachmakov I, Rekersbrink S, Hofmann U, Eichelbaum M, Fromm MF: Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2005 Mar;371(3):195-201. Epub 2005       Apr 15.</reference_text>
        <pubmed_id>15900513</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propafenone</name>
        <accession>HMDB15313</accession>
      </metabolite>
      <reference>
        <reference_text>Singh P, Paul K: Studies of interactions between uracil-based hybrid molecules and P-glycoprotein--search for multidrug resistance modulators. Bioorg Med Chem. 2006 Nov 1;14(21):7183-6. Epub 2006 Jul 14.</reference_text>
        <pubmed_id>16843673</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propafenone</name>
        <accession>HMDB15313</accession>
      </metabolite>
      <reference>
        <reference_text>Woodland C, Verjee Z, Giesbrecht E, Koren G, Ito S: The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell monolayers. J Pharmacol Exp Ther. 1997 Oct;283(1):39-45.</reference_text>
        <pubmed_id>9336306</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propafenone</name>
        <accession>HMDB15313</accession>
      </metabolite>
      <reference>
        <reference_text>Tmej C, Chiba P, Huber M, Richter E, Hitzler M, Schaper KJ, Ecker G: A combined Hansch/Free-Wilson approach as predictive tool in QSAR studies on propafenone-type modulators of multidrug resistance. Arch Pharm (Weinheim). 1998 Jul-Aug;331(7-8):233-40.</reference_text>
        <pubmed_id>9747179</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Domperidone</name>
        <accession>HMDB15315</accession>
      </metabolite>
      <reference>
        <reference_text>Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.</reference_text>
        <pubmed_id>12954186</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Domperidone</name>
        <accession>HMDB15315</accession>
      </metabolite>
      <reference>
        <reference_text>Schinkel AH, Wagenaar E, Mol CA, van Deemter L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996 Jun 1;97(11):2517-24.</reference_text>
        <pubmed_id>8647944</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acebutolol</name>
        <accession>HMDB15324</accession>
      </metabolite>
      <reference>
        <reference_text>Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24.</reference_text>
        <pubmed_id>12948019</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acebutolol</name>
        <accession>HMDB15324</accession>
      </metabolite>
      <reference>
        <reference_text>Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A: Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol. 1996 Oct;48(10):1083-9.</reference_text>
        <pubmed_id>8953513</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estramustine</name>
        <accession>HMDB15327</accession>
      </metabolite>
      <reference>
        <reference_text>Yang CP, Shen HJ, Horwitz SB: Modulation of the function of P-glycoprotein by estramustine.  J Natl Cancer Inst. 1994 May 4;86(9):723-5.</reference_text>
        <pubmed_id>7908991</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estramustine</name>
        <accession>HMDB15327</accession>
      </metabolite>
      <reference>
        <reference_text>Tiersten AD, Nelsen C, Talbot S, Vahdat L, Fine R, Troxel A, Brafman L, Shriberg L, Antman K, Petrylak DP: A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer. 2003 Feb 1;97(3):537-44.</reference_text>
        <pubmed_id>12548594</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estramustine</name>
        <accession>HMDB15327</accession>
      </metabolite>
      <reference>
        <reference_text>Smith CD, Zilfou JT, Zhang X, Hudes GR, Tew KD: Modulation of P-glycoprotein activity by estramustine is limited by binding to plasma proteins. Cancer. 1995 May 15;75(10):2597-604.</reference_text>
        <pubmed_id>7736407</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estramustine</name>
        <accession>HMDB15327</accession>
      </metabolite>
      <reference>
        <reference_text>Speicher LA, Barone LR, Chapman AE, Hudes GR, Laing N, Smith CD, Tew KD: P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J Natl Cancer Inst. 1994 May 4;86(9):688-94.</reference_text>
        <pubmed_id>7908988</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Captopril</name>
        <accession>HMDB15328</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1.  Life Sci. 2002 Feb 15;70(13):1491-500.</reference_text>
        <pubmed_id>11895100</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromocriptine</name>
        <accession>HMDB15331</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73.</reference_text>
        <pubmed_id>11961113</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromocriptine</name>
        <accession>HMDB15331</accession>
      </metabolite>
      <reference>
        <reference_text>Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.  J Pharmacol Exp Ther. 2002 Oct;303(1):323-32.</reference_text>
        <pubmed_id>12235267</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromocriptine</name>
        <accession>HMDB15331</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromocriptine</name>
        <accession>HMDB15331</accession>
      </metabolite>
      <reference>
        <reference_text>Renaud JP, Davydov DR, Heirwegh KP, Mansuy D, Hui Bon Hoa GH: Thermodynamic studies of substrate binding and spin transitions in human cytochrome P-450 3A4 expressed in yeast microsomes. Biochem J. 1996 Nov 1;319 ( Pt 3):675-81.</reference_text>
        <pubmed_id>8920966</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levetiracetam</name>
        <accession>HMDB15333</accession>
      </metabolite>
      <reference>
        <reference_text>Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10.</reference_text>
        <pubmed_id>17045309</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levetiracetam</name>
        <accession>HMDB15333</accession>
      </metabolite>
      <reference>
        <reference_text>Luna-Tortos C, Fedrowitz M, Loscher W: Several major antiepileptic drugs are substrates for human P-glycoprotein.  Neuropharmacology. 2008 Dec;55(8):1364-75. Epub 2008 Sep 11.</reference_text>
        <pubmed_id>18824002</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nadolol</name>
        <accession>HMDB15334</accession>
      </metabolite>
      <reference>
        <reference_text>Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A: Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol. 1996 Oct;48(10):1083-9.</reference_text>
        <pubmed_id>8953513</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Schrenk D, Michalke A, Gant TW, Brown PC, Silverman JA, Thorgeirsson SS: Multidrug resistance gene expression in rodents and rodent hepatocytes treated with mitoxantrone. Biochem Pharmacol. 1996 Nov 8;52(9):1453-60.</reference_text>
        <pubmed_id>8937457</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Taipalensuu J, Tavelin S, Lazorova L, Svensson AC, Artursson P: Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. Eur J Pharm Sci. 2004 Jan;21(1):69-75.</reference_text>
        <pubmed_id>14706813</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. Epub 2009 May 12.</reference_text>
        <pubmed_id>19493273</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flumazenil</name>
        <accession>HMDB15336</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sparfloxacin</name>
        <accession>HMDB15339</accession>
      </metabolite>
      <reference>
        <reference_text>Naruhashi K, Tamai I, Inoue N, Muraoka H, Sai Y, Suzuki N, Tsuji A: Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein. J Pharm Pharmacol. 2001 May;53(5):699-709.</reference_text>
        <pubmed_id>11370709</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sparfloxacin</name>
        <accession>HMDB15339</accession>
      </metabolite>
      <reference>
        <reference_text>Cormet-Boyaka E, Huneau JF, Mordrelle A, Boyaka PN, Carbon C, Rubinstein E, Tome D: Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors. Antimicrob Agents Chemother. 1998 Oct;42(10):2607-11.</reference_text>
        <pubmed_id>9756763</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clarithromycin</name>
        <accession>HMDB15342</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clarithromycin</name>
        <accession>HMDB15342</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clarithromycin</name>
        <accession>HMDB15342</accession>
      </metabolite>
      <reference>
        <reference_text>Egashira K, Ohtani H, Itoh S, Koyabu N, Tsujimoto M, Murakami H, Sawada Y: Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein. Drug Metab Dispos. 2004 Aug;32(8):828-33.</reference_text>
        <pubmed_id>15258108</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clarithromycin</name>
        <accession>HMDB15342</accession>
      </metabolite>
      <reference>
        <reference_text>[No authors listed]Clarithromycin.  Tuberculosis (Edinb). 2008 Mar;88(2):92-5.</reference_text>
        <pubmed_id>18486039</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clarithromycin</name>
        <accession>HMDB15342</accession>
      </metabolite>
      <reference>
        <reference_text>Dey S, Gunda S, Mitra AK: Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption. J Pharmacol Exp Ther. 2004 Oct;311(1):246-55. Epub 2004 Jun 2.</reference_text>
        <pubmed_id>15175422</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Jang SH, Wientjes MG, Au JL: Kinetics of P-glycoprotein-mediated efflux of paclitaxel.  J Pharmacol Exp Ther. 2001 Sep;298(3):1236-42.</reference_text>
        <pubmed_id>11504826</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Li D, Jang SH, Kim J, Wientjes MG, Au JL: Enhanced drug-induced apoptosis associated with P-glycoprotein overexpression is specific to antimicrotubule agents. Pharm Res. 2003 Jan;20(1):45-50.</reference_text>
        <pubmed_id>12608535</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24.</reference_text>
        <pubmed_id>12948019</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Kim S, Kim SS, Bang YJ, Kim SJ, Lee BJ: In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. Peptides. 2003 Jul;24(7):945-53.</reference_text>
        <pubmed_id>14499271</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Walle UK, Walle T: Taxol transport by human intestinal epithelial Caco-2 cells.  Drug Metab Dispos. 1998 Apr;26(4):343-6.</reference_text>
        <pubmed_id>9531522</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35.</reference_text>
        <pubmed_id>10617675</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26.</reference_text>
        <pubmed_id>15180340</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY: BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res. 2004 Jul 1;64(13):4621-8.</reference_text>
        <pubmed_id>15231674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Li YC, Fung KP, Kwok TT, Lee CY, Suen YK, Kong SK: Mitochondria-targeting drug oligomycin blocked P-glycoprotein activity and triggered apoptosis in doxorubicin-resistant HepG2 cells. Chemotherapy. 2004 Jun;50(2):55-62.</reference_text>
        <pubmed_id>15211078</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Kwak JO, Lee SH, Lee GS, Kim MS, Ahn YG, Lee JH, Kim SW, Kim KH, Lee MG: Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel. Eur J Pharmacol. 2010 Feb 10;627(1-3):92-8. Epub 2009 Nov 10.</reference_text>
        <pubmed_id>19903471</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ: MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8. Epub 2009 Jan 4.</reference_text>
        <pubmed_id>19123050</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. Epub 2009 Apr 11.</reference_text>
        <pubmed_id>19427995</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. Epub 2009 May 12.</reference_text>
        <pubmed_id>19493273</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Saquinavir</name>
        <accession>HMDB15362</accession>
      </metabolite>
      <reference>
        <reference_text>Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ: Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 2000 Jun 16;14(9):1287-9.</reference_text>
        <pubmed_id>10894301</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Saquinavir</name>
        <accession>HMDB15362</accession>
      </metabolite>
      <reference>
        <reference_text>Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60.</reference_text>
        <pubmed_id>10820137</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Saquinavir</name>
        <accession>HMDB15362</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Saquinavir</name>
        <accession>HMDB15362</accession>
      </metabolite>
      <reference>
        <reference_text>Kim AE, Dintaman JM, Waddell DS, Silverman JA: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein.  J Pharmacol Exp Ther. 1998 Sep;286(3):1439-45.</reference_text>
        <pubmed_id>9732409</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Saquinavir</name>
        <accession>HMDB15362</accession>
      </metabolite>
      <reference>
        <reference_text>Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH: P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol. 2001 Apr;59(4):806-13.</reference_text>
        <pubmed_id>11259625</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Saquinavir</name>
        <accession>HMDB15362</accession>
      </metabolite>
      <reference>
        <reference_text>Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24.</reference_text>
        <pubmed_id>12948019</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Saquinavir</name>
        <accession>HMDB15362</accession>
      </metabolite>
      <reference>
        <reference_text>Eagling VA, Profit L, Back DJ: Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol. 1999 Oct;48(4):543-52.</reference_text>
        <pubmed_id>10583025</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Saquinavir</name>
        <accession>HMDB15362</accession>
      </metabolite>
      <reference>
        <reference_text>Collett A, Tanianis-Hughes J, Hallifax D, Warhurst G: Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a(-/-) mice in vivo. Pharm Res. 2004 May;21(5):819-26.</reference_text>
        <pubmed_id>15180340</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexamethasone</name>
        <accession>HMDB15364</accession>
      </metabolite>
      <reference>
        <reference_text>Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31.</reference_text>
        <pubmed_id>11297522</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexamethasone</name>
        <accession>HMDB15364</accession>
      </metabolite>
      <reference>
        <reference_text>Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91.</reference_text>
        <pubmed_id>12387747</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexamethasone</name>
        <accession>HMDB15364</accession>
      </metabolite>
      <reference>
        <reference_text>Schuetz JD, Silverman JA, Thottassery JV, Furuya KN, Schuetz EG: Divergent regulation of the class II P-glycoprotein gene in primary cultures of hepatocytes versus H35 hepatoma by glucocorticoids. Cell Growth Differ. 1995 Oct;6(10):1321-32.</reference_text>
        <pubmed_id>8845310</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexamethasone</name>
        <accession>HMDB15364</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexamethasone</name>
        <accession>HMDB15364</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexamethasone</name>
        <accession>HMDB15364</accession>
      </metabolite>
      <reference>
        <reference_text>Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.</reference_text>
        <pubmed_id>11785684</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexamethasone</name>
        <accession>HMDB15364</accession>
      </metabolite>
      <reference>
        <reference_text>Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids.  Pharm Res. 2003 Nov;20(11):1794-803.</reference_text>
        <pubmed_id>14661924</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexamethasone</name>
        <accession>HMDB15364</accession>
      </metabolite>
      <reference>
        <reference_text>Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P: Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995 Oct;96(4):1698-705.</reference_text>
        <pubmed_id>7560060</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorprothixene</name>
        <accession>HMDB15369</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomipramine</name>
        <accession>HMDB15372</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bepridil</name>
        <accession>HMDB15374</accession>
      </metabolite>
      <reference>
        <reference_text>Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83.</reference_text>
        <pubmed_id>11082465</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Docetaxel</name>
        <accession>HMDB15378</accession>
      </metabolite>
      <reference>
        <reference_text>Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D: Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol. 1994 Oct 7;48(7):1528-30.</reference_text>
        <pubmed_id>7945455</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Docetaxel</name>
        <accession>HMDB15378</accession>
      </metabolite>
      <reference>
        <reference_text>Shirakawa K, Takara K, Tanigawara Y, Aoyama N, Kasuga M, Komada F, Sakaeda T, Okumura K: Interaction of docetaxel ("Taxotere") with human P-glycoprotein.  Jpn J Cancer Res. 1999 Dec;90(12):1380-6.</reference_text>
        <pubmed_id>10665657</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergonovine</name>
        <accession>HMDB15383</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73.</reference_text>
        <pubmed_id>11961113</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergonovine</name>
        <accession>HMDB15383</accession>
      </metabolite>
      <reference>
        <reference_text>Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.  J Pharmacol Exp Ther. 2002 Oct;303(1):323-32.</reference_text>
        <pubmed_id>12235267</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dasatinib</name>
        <accession>HMDB15384</accession>
      </metabolite>
      <reference>
        <reference_text>Dohse M, Scharenberg C, Shukla S, Robey RW, Volkmann T, Deeken JF, Brendel C, Ambudkar SV, Neubauer A, Bates SE: Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib. Drug Metab Dispos. 2010 Aug;38(8):1371-80. Epub 2010 Apr 27.</reference_text>
        <pubmed_id>20423956</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dasatinib</name>
        <accession>HMDB15384</accession>
      </metabolite>
      <reference>
        <reference_text>Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. Epub 2009 Sep 28.</reference_text>
        <pubmed_id>19785662</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dasatinib</name>
        <accession>HMDB15384</accession>
      </metabolite>
      <reference>
        <reference_text>Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE: Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood. 2008 Oct 15;112(8):3348-54. Epub 2008 Jul 31.</reference_text>
        <pubmed_id>18669873</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lapatinib</name>
        <accession>HMDB15388</accession>
      </metabolite>
      <reference>
        <reference_text>Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW: Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 2008 Oct 1;68(19):7905-14.</reference_text>
        <pubmed_id>18829547</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sitagliptin</name>
        <accession>HMDB15390</accession>
      </metabolite>
      <reference>
        <reference_text>Scheen AJ: Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.  Diabetes Obes Metab. 2010 Aug;12(8):648-58.</reference_text>
        <pubmed_id>20590741</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Posaconazole</name>
        <accession>HMDB15392</accession>
      </metabolite>
      <reference>
        <reference_text>Nagappan V, Deresinski S: Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis. 2007 Dec 15;45(12):1610-7.</reference_text>
        <pubmed_id>18190324</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sunitinib</name>
        <accession>HMDB15397</accession>
      </metabolite>
      <reference>
        <reference_text>Hu S, Chen Z, Franke R, Orwick S, Zhao M, Rudek MA, Sparreboom A, Baker SD: Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009 Oct 1;15(19):6062-9. Epub 2009 Sep 22.</reference_text>
        <pubmed_id>19773380</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sunitinib</name>
        <accession>HMDB15397</accession>
      </metabolite>
      <reference>
        <reference_text>Shukla S, Robey RW, Bates SE, Ambudkar SV: Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos. 2009 Feb;37(2):359-65. Epub 2008 Oct 29.</reference_text>
        <pubmed_id>18971320</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vecuronium</name>
        <accession>HMDB15432</accession>
      </metabolite>
      <reference>
        <reference_text>Smit JW, Weert B, Schinkel AH, Meijer DK: Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs. J Pharmacol Exp Ther. 1998 Jul;286(1):321-7.</reference_text>
        <pubmed_id>9655875</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cilazapril</name>
        <accession>HMDB15433</accession>
      </metabolite>
      <reference>
        <reference_text>Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1.  Life Sci. 2002 Feb 15;70(13):1491-500.</reference_text>
        <pubmed_id>11895100</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Troleandomycin</name>
        <accession>HMDB15448</accession>
      </metabolite>
      <reference>
        <reference_text>Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5.</reference_text>
        <pubmed_id>11716514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Troleandomycin</name>
        <accession>HMDB15448</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA: Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol Pharmacol. 2002 May;61(5):964-73.</reference_text>
        <pubmed_id>11961113</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Troleandomycin</name>
        <accession>HMDB15448</accession>
      </metabolite>
      <reference>
        <reference_text>Yasuda K, Lan LB, Sanglard D, Furuya K, Schuetz JD, Schuetz EG: Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.  J Pharmacol Exp Ther. 2002 Oct;303(1):323-32.</reference_text>
        <pubmed_id>12235267</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Colchicine</name>
        <accession>HMDB15466</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Colchicine</name>
        <accession>HMDB15466</accession>
      </metabolite>
      <reference>
        <reference_text>Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25.</reference_text>
        <pubmed_id>12699389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Colchicine</name>
        <accession>HMDB15466</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Colchicine</name>
        <accession>HMDB15466</accession>
      </metabolite>
      <reference>
        <reference_text>Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24.</reference_text>
        <pubmed_id>12948019</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Colchicine</name>
        <accession>HMDB15466</accession>
      </metabolite>
      <reference>
        <reference_text>Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, Pastan I: Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8472-6.</reference_text>
        <pubmed_id>1356264</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Colchicine</name>
        <accession>HMDB15466</accession>
      </metabolite>
      <reference>
        <reference_text>Bebawy M, Morris MB, Roufogalis BD: A continuous fluorescence assay for the study of P-glycoprotein-mediated drug efflux using inside-out membrane vesicles. Anal Biochem. 1999 Mar 15;268(2):270-7.</reference_text>
        <pubmed_id>10075817</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Colchicine</name>
        <accession>HMDB15466</accession>
      </metabolite>
      <reference>
        <reference_text>Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY: BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res. 2004 Jul 1;64(13):4621-8.</reference_text>
        <pubmed_id>15231674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Colchicine</name>
        <accession>HMDB15466</accession>
      </metabolite>
      <reference>
        <reference_text>Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. Epub 2009 Apr 11.</reference_text>
        <pubmed_id>19427995</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digitoxin</name>
        <accession>HMDB15468</accession>
      </metabolite>
      <reference>
        <reference_text>Pauli-Magnus C, Murdter T, Godel A, Mettang T, Eichelbaum M, Klotz U, Fromm MF: P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin. Naunyn Schmiedebergs Arch Pharmacol. 2001 Mar;363(3):337-43.</reference_text>
        <pubmed_id>11284449</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Neostigmine</name>
        <accession>HMDB15472</accession>
      </metabolite>
      <reference>
        <reference_text>Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery.  J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.</reference_text>
        <pubmed_id>11602674</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Liotrix</name>
        <accession>HMDB15523</accession>
      </metabolite>
      <reference>
        <reference_text>Siegmund W, Altmannsberger S, Paneitz A, Hecker U, Zschiesche M, Franke G, Meng W, Warzok R, Schroeder E, Sperker B, Terhaag B, Cascorbi I, Kroemer HK: Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition. Clin Pharmacol Ther. 2002 Sep;72(3):256-64.</reference_text>
        <pubmed_id>12235446</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Liotrix</name>
        <accession>HMDB15523</accession>
      </metabolite>
      <reference>
        <reference_text>Ashida K, Katsura T, Motohashi H, Saito H, Inui K: Thyroid hormone regulates the activity and expression of the peptide transporter PEPT1 in Caco-2 cells. Am J Physiol Gastrointest Liver Physiol. 2002 Apr;282(4):G617-23.</reference_text>
        <pubmed_id>11897620</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketazolam</name>
        <accession>HMDB15526</accession>
      </metabolite>
      <reference>
        <reference_text>Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35.</reference_text>
        <pubmed_id>11181899</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketazolam</name>
        <accession>HMDB15526</accession>
      </metabolite>
      <reference>
        <reference_text>Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.</reference_text>
        <pubmed_id>11785684</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitrazepam</name>
        <accession>HMDB15534</accession>
      </metabolite>
      <reference>
        <reference_text>Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37.</reference_text>
        <pubmed_id>12438524</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lopinavir</name>
        <accession>HMDB15539</accession>
      </metabolite>
      <reference>
        <reference_text>Vishnuvardhan D, Moltke LL, Richert C, Greenblatt DJ: Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS. 2003 May 2;17(7):1092-4.</reference_text>
        <pubmed_id>12700464</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Genistein</name>
        <accession>HMDB03217</accession>
      </metabolite>
      <reference>
        <reference_text>Castro AF, Altenberg GA: Inhibition of drug transport by genistein in multidrug-resistant cells expressing P-glycoprotein. Biochem Pharmacol. 1997 Jan 10;53(1):89-93.</reference_text>
        <pubmed_id>8960067</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Genistein</name>
        <accession>HMDB03217</accession>
      </metabolite>
      <reference>
        <reference_text>Versantvoort CH, Rhodes T, Twentyman PR: Acceleration of MRP-associated efflux of rhodamine 123 by genistein and related compounds. Br J Cancer. 1996 Dec;74(12):1949-54.</reference_text>
        <pubmed_id>8980395</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Genistein</name>
        <accession>HMDB03217</accession>
      </metabolite>
      <reference>
        <reference_text>Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9.</reference_text>
        <pubmed_id>14985103</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cholic acid</name>
        <accession>HMDB00619</accession>
      </metabolite>
      <reference>
        <reference_text>Fickert P, Zollner G, Fuchsbichler A, Stumptner C, Pojer C, Zenz R, Lammert F, Stieger B, Meier PJ, Zatloukal K, Denk H, Trauner M: Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology. 2001 Jul;121(1):170-83.</reference_text>
        <pubmed_id>11438506</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glycerol</name>
        <accession>HMDB00131</accession>
      </metabolite>
      <reference>
        <reference_text>Konishi T, Satsu H, Hatsugai Y, Aizawa K, Inakuma T, Nagata S, Sakuda SH, Nagasawa H, Shimizu M: Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells. Br J Pharmacol. 2004 Oct;143(3):379-87. Epub 2004 Sep 6.</reference_text>
        <pubmed_id>15351776</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Mazzanti R, Fantappie O, Kamimoto Y, Gatmaitan Z, Gentilini P, Arias IM: Bile acid inhibition of P-glycoprotein-mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles. Hepatology. 1994 Jul;20(1 Pt 1):170-6.</reference_text>
        <pubmed_id>7912687</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Taurocholic acid</name>
        <accession>HMDB00036</accession>
      </metabolite>
      <reference>
        <reference_text>Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, Lan LB, Schuetz JD: Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Mol Pharmacol. 2000 Jan;57(1):24-35.</reference_text>
        <pubmed_id>10617675</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cholesterol</name>
        <accession>HMDB00067</accession>
      </metabolite>
      <reference>
        <reference_text>Wang E, Casciano CN, Clement RP, Johnson WW: Cholesterol interaction with the daunorubicin binding site of P-glycoprotein.  Biochem Biophys Res Commun. 2000 Oct 5;276(3):909-16.</reference_text>
        <pubmed_id>11027568</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estriol</name>
        <accession>HMDB00153</accession>
      </metabolite>
      <reference>
        <reference_text>Kim WY, Benet LZ: P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93.</reference_text>
        <pubmed_id>15290871</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nilotinib</name>
        <accession>HMDB15595</accession>
      </metabolite>
      <reference>
        <reference_text>Tiwari AK, Sodani K, Wang SR, Kuang YH, Ashby CR Jr, Chen X, Chen ZS: Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61. Epub 2009 Apr 11.</reference_text>
        <pubmed_id>19427995</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nilotinib</name>
        <accession>HMDB15595</accession>
      </metabolite>
      <reference>
        <reference_text>Hegedus C, Ozvegy-Laczka C, Apati A, Magocsi M, Nemet K, Orfi L, Keri G, Katona M, Takats Z, Varadi A, Szakacs G, Sarkadi B: Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol. 2009 Oct;158(4):1153-64. Epub 2009 Sep 28.</reference_text>
        <pubmed_id>19785662</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nilotinib</name>
        <accession>HMDB15595</accession>
      </metabolite>
      <reference>
        <reference_text>Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. Epub 2010 Sep 1.</reference_text>
        <pubmed_id>20810928</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Voacamine</name>
        <accession>HMDB15597</accession>
      </metabolite>
      <reference>
        <reference_text>Meschini S, Marra M, Condello M, Calcabrini A, Federici E, Dupuis ML, Cianfriglia M, Arancia G: Voacamine, an alkaloid extracted from Peschiera fuchsiaefolia, inhibits P-glycoprotein action in multidrug-resistant tumor cells. Int J Oncol. 2005 Dec;27(6):1597-603.</reference_text>
        <pubmed_id>16273216</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Voacamine</name>
        <accession>HMDB15597</accession>
      </metabolite>
      <reference>
        <reference_text>Meschini S, Marra M, Calcabrini A, Federici E, Galeffi C, Arancia G: Voacamine, a bisindolic alkaloid from Peschiera fuchsiaefolia, enhances the cytotoxic effect of doxorubicin on multidrug-resistant tumor cells. Int J Oncol. 2003 Dec;23(6):1505-13.</reference_text>
        <pubmed_id>14612920</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dabigatran etexilate</name>
        <accession>HMDB15641</accession>
      </metabolite>
      <reference>
        <reference_text>Galanis T, Thomson L, Palladino M, Merli GJ: New oral anticoagulants.  J Thromb Thrombolysis. 2011 Apr;31(3):310-20.</reference_text>
        <pubmed_id>21327511</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
